糖痹康干预糖尿病周围神经病变临床及作用机制研究
|
摘要
[研究背景]
糖尿病周围神经病变(Diabetic peripheral neuropathy,DPN)是糖尿病(Diabetes mellitus, DM)常见并发症之一,临床上常常累及DPN患者的感觉神经及植物神经,使之产生刺痛、麻木甚至导致运动及神经功能障碍,发病率较高,严重危害患者的身体健康,是糖尿病病人致残的首要因素。DPN发病机制十分复杂,非单一因素所致,尚未完全阐明,造成西医对其治疗存在一定的局限性和有效性；中医药对DPN具有多手段、多途径、多靶点整体治疗优势和明显疗效。导师刘铜华教授经过多年的临床研究,认为本病主要病机为“气阴不足,毒瘀神络”,并在国内外首次提出“益气养阴、解毒化瘀通络”的新治疗原则。本课题在前期研究基础上,通过实验及临床研究,进一步探讨中药复方糖痹康对DPN神经保护机制及作用靶点,为临床推广应用提供理论依据。
[研究目的]
临床研究采用自身前后对照方法,客观评价临床有效复方中药糖痹康治疗糖尿病周围神经病变的临床有效性及安全性；实验研究通过动物及细胞模型,从分子水平探讨糖痹康作用机制。
[研究方法]
临床研究采用自身前后对照,观察中药复方糖痹康对35例DPN患者的临床疗效。在基础治疗(如血糖、血压、血脂等)的基础上,给予35例DPN病人口服糖痹康配方颗粒,治疗8周后,对病人的各项指标(如：中医证候、实验室检查及肌电图)进行客观评价。
实验研究
1整体实验
采用高脂饲料和小剂量链脲佐菌素诱发2型糖尿病大鼠动物模型,不同剂量的糖痹康灌胃,并与弥可保对照,每4周检测体重、空腹血糖和坐骨神经传导速度；16周后,光镜观察各组大鼠坐骨神经病理变化、电镜观察坐骨神经超微结构；采用酶法测定TC、 TG;采用免疫比浊法测定HDL-C、LDL-C;放射免疫法检测大鼠血浆β-EP、ET、FINS水平；铜试纸显色法检测大鼠血清NEFA、NO水平；免疫组织化学法和western blot检测坐骨神经NGF、BDNF、NT-3、VEGF蛋白表达；实时荧光定量RT-PCR检测NGF、BDNF. NT-3、VEGF mRNA表达。
2细胞实验
通过雪旺细胞株,建立高糖环境下大鼠雪旺细胞的细胞模型；用不同剂量的含药血清和正常血清培养基刺激24h、48h、72h和96h后,MTT法检测高糖环境下不同剂量的糖痹康含药血清对大鼠细胞增殖的影响；并用不同剂量的含药血清和正常血清培养基刺激48h后,采用放免法检测细胞上清中TNF-α的含量；ELISA法检测细胞上清中sVCAM-1的含量,Western blot法检测大鼠雪旺细胞P38和P-P38的表达。
[研究结果]
临床研究糖痹康治疗前后受试对象的双侧胫运动神经(MCv)、感觉神经(SCv)传导速度明显改善(P<0.05),且治疗前后安全性指标(血糖、糖化血红蛋白、血脂及血压)均在正常范围内,无显著性差异(P>0.05)同时未出现不良反应；总有效率达到91.14%。
实验研究：
1整体实验
与正常组比较,模型组体重均显著降低,血糖均显著升高,坐骨神经传导速率均显著降低,NO、β-EP、FINS、HDL-C、NGF的蛋白及mRNA、BDNF的蛋白及mRNA、NT-3的蛋白及mRNA的含量均显著降低,ET、TG、TC、LDL-C、NEFA、VEGF的蛋白及mRNA的含量均显著升高。与模型组比较,糖痹康及弥可保组体重均显著升高,血糖均显著降低,坐骨神经传导速率均显著升高,NO、β-EP、FINS、HDL-C、NGF的蛋白及mRNA、BDNF的蛋白及nRNA、NT-3的蛋白及mRNA的含量均显著升高,ET、TG、 TC、LDL-C、NEFA、VEGF的蛋白及nRNA的含量均显著降低。病理检测显示,正常组大鼠坐骨神经纤维结构紧密、分布均匀、排列整齐；模型组大鼠坐骨神经纤维排列疏松、间隙变大、多处发生变性及断裂；各给药组大鼠坐骨神经纤维的变性与断裂显著减少,纤维结构紧密、排列整齐,未见变性与断裂的发生,髓鞘变厚且着色均匀。电镜结果显示,正常组大鼠坐骨神经横切面髓鞘结构完整、致密、均匀；模型组大鼠坐骨神经横切面髓鞘的板层结构发生严重分离,各层间排列紊乱,出现大量空泡及裂隙；各给药组坐骨神经中空泡及裂隙均显著降低,但髓鞘仍未恢复板层状结构,线粒体及粗面内质网结构正常,出现结构完整的雪旺细胞。
2细胞实验
与空白组比较,24、48、72、96小时后,50MGLU与75MGLU组细胞增殖程度均显著降低,但50M GLU与75M GLU组间并无差异；与50mM高糖对照组比较,24、48小时后,弥可保及糖痹康1:1、1：2、1：8组均可显著增高细胞增殖能力。
与空白对照组比较,50mM高糖对照组的sVCAM-1、TNF-α、P38丝裂素活化蛋白激酶及磷酸化P38丝裂素活化蛋白激酶含量显著升高；与50mM高糖对照组比较,弥可保与糖痹康各剂量组上清中sVCAM-1、TNF-α、P38丝裂素活化蛋白激酶及磷酸化P38丝裂素活化蛋白激酶的含量显著降低。
[结论]
临床观察中药复方糖痹康可显著改善DPN患者的临床症状、提高神经传导速度、显著降低国际公认糖尿病周围神经病变积分并且总有效率达到91.14%。
实验研究
1整体实验：
(1)中药复方糖痹康能改善STZ-DM大鼠血糖、体重及血脂；降低DPN大鼠血清游离脂肪酸水平；改善糖尿病周围神经病变大鼠坐骨神经传导速度且存在剂量与用药时间依赖关系；
(2)中药复方糖痹康对DPN大鼠坐骨神经的形态具有保护作用以及对其坐骨神经髓鞘、轴索等具有修复作用；
(3)中药复方糖痹康能上调DPN大鼠FINS的表达、血清中NO的表达及下调血浆中ET的表达,这些可能是其防治DPN的机制之一；
(4)中药复方糖痹康能显著上调DPN大鼠血浆中p-EP的表达,这可能是其对糖尿病周围神经病变的神经保护及镇痛作用的机制之一；
(5)中药复方糖痹康能显著上调DPN大鼠坐骨神经中NGF、BDNF、NT-3蛋白及基因表达,下调DPN大鼠坐骨神经中VEGF蛋白及基因表达,这些可能是其防治DPN的有效作用靶点之一。
2细胞实验：
(1)糖痹康组可明显改善高糖培养环境下,雪旺细胞增殖活性,糖痹康低剂量组优于西药(弥可保)组,其在高糖培养的环境下,中医复方糖痹康可促进大鼠坐骨神经雪旺细胞的增殖,可能是其防治DPN的机制之一；
(2)糖痹康含药血清可下调在高糖环境下大鼠坐骨神经雪旺细胞p38MAPK及其激活形式p-p38MAPK蛋白表达,及下调大鼠坐骨神经雪旺细胞上清中TNF-α的含量,可能是其DPN神经保护及镇痛作用靶点之一；
(3)糖痹康含药血清可下调大鼠坐骨神经雪旺细胞上清中sVCAM-1的含量,可能是其DPN神经保护作用靶点之一。
[Study background]
Diabetic peripheral neuropathy (Diabetic peripheral neuropathy, DPN) is a common complication of diabetes mellitus (DM). DPN often involves sensory nerve and plant nerve, causing tingling, numbness, and even lead to exercise and nerve dysfunction in clinical. With high rate of incidence, it damages to health seriously and leads primary diabetes to disability. The world health organization estimates that there will be about360million DM patients in the world by2030, most of who suffer type2diabetes mellitus DPN. The pathogenesis of DPN is very complex and have not been fully elucidated causing limitation to the western medicine for the treatment and effectiveness yet. Traditional Chinese medicine treating DPN has overall advantages and obvious curative effect for its various means and ways. In recent years, there are many useful researches about DPN disease name, pathogenesis, clinical syndrome differentiation and treatment. The holistie therapy of DPN using TCM has its advantages and obviously curative effect. Professor Tonghua Liu insist the pathogenesis of DPN were deficiency of qi yin and poison stuck the shen collateral and brings up the new therapy of nourishing yin and qi, detoxify, dispersing blood stasis and clear the collateral. This project discusses the nerve protection mechanisms and targets of Chinese herbal compound Tangbikang treating DPN on the basis of previous research, and provides clinical basis of clinical application.
[Objective]
To objective evaluation of clinical efficacy and safety of treatment of diabetic peripheral neuropathy by Chinese herbal compound Tangbikang, the clinical trials were adopted by self control.
[Methods]
Clinic trial
35DPN patients conforming to the diagnostic criteria, based on the basic treatment for blood pressure, blood glucose and blood lipid, were given Chinese herbal compound Tangbikang. After curing for8weeks, we measured some indicators, like TCM syndrome, laboratory examination and electromyography.
Experimental research
1.vivo experiments
The experimental diabetes mellitus rats model were induced by feeding high fat forage and injection streptozotocin. Tangbikang groups were given Tangbikang with different dose, Body weight, blood glucose and sciatic nerves conduction velocitywere detected in every4weeks. Rats unilateral sciatic nerve were cutting-up after16weeks, pathological change of rat sciatic nerve of each group was observed with the light microscope, ultrastructure of rat sciatic nerve was observed by electron microscopy; the TC and TG were determined by the enzyme analysis method, the HDL-C and LDL-Cwere determined by immunoturbidimetry method; the p-EP,ET and FINS levels of rat plasma were determined by radioimmunoassay; the NEFA and NO levels of rat serum weredetermined by the method of Cul test paper; the expressions of NGF, BDNF, NT-3and VEGFproteinof rat sciatic nerve were determined by immunohistochemical assay and western blot; the expressions of NGF, BDNF, NT-3,and VEGF mRNA were detected by real-time fluorescence quantification.
2.vitro experiment
schwann cell model was establish in high glucose environment from schwann cells lineage.The effect of different dose Tangbikangon the proliferation of rat epidermal cells was detect by MTT method after stimulate by drug serum of different dose and serum at24h,48h,72h and96h. The content of TNF-a in supernatants were determined by radioimmunoassay after stimulate by drug serum of different dose and serum at48h; the content of sVCAM-1in supernatants were determined byELISA method; the expressions of schwann cell P38and P-P38were detected by Western blot method.
[Results]
Clinical trial
After the treatment byTangbikang, the conduction velocitiesof MCv and SCvwas better than before, the difference was significant (P<0.05).Security Indexincludingblood glucose, glycosylated hemoglobin, blood lipid and blood pressurewith normal limits, the difference was insignificant (P>0.05), and there were no obvious side effects has been found during the treatment; the total effective rate of the Tangbikang was91.14%.
Experimental research
1.vivo experiments
Compared with normal group, model group weight was significantly reduced, the blood glucose was significantlyrisen, sciatic nerves conduction velocity were significantly reduced, the content of NO,β-EP, FINS,HDL-C, protein and mRNA of NGF, protein and mRNA of BDNF and protein and mRNA of NT-3were significantly risen; the content of ET, TG, TC、LDL-C、NEFA、protein and mRNA of VEGF were significantly reduced. Compared with model group, the rats body weight with different doses of Tangbikang were significantly increased; the content of NO,β-EP HDL-C,FINS, protein and mRNA of NGF, protein and mRNA of BDNF and protein and mRNA of NT-3were significantly reduced; the content of ET、TG、TC、LDL-C、NEFA、protein and mRNA of VEGF were significantly risen. The pathological results showed that sciatic nervefiber of normal group was hard-packed, homogeneous distribution and in alignment; and looselyarranged, larger gap and degeneration and fracture in multiple places of model group; degeneration and fracture of sciatic nerve was significantly reduced in Tangbikang group, it was hard-packed, homogeneous distribution and in alignment, but has degeneration and fracture insome places, the myelin sheath was thickened and even colouring. Electron microscopy (sem) results showed that the sciatic nervemyelin sheath was structural integrity, densification and well-distributed in normal group, the sciatic nervemyelin sheath was serious separation of lamellar structure, a disordered arrangement between each layer and a large number of vacuoles and gaps were in control group, the vacuoles and gaps of sciatic nerve were significantly reduced in Tangbikang group, but the lamellar structure was also abnormal, the structures of mitochondria and rough endoplasmic reticulum were in normality, structural integrityschwann cell was observed.
2.vitro experiment
Compared with blank group,50M GLU and75M GLU groups, the degree of cell proliferation was significantly reduced after24h,48h,72h and96h, but there were no significantly difference between50M GLU and75M GLU group. Compared with50mM model group, the degree of cell proliferation wassignificantly risenin Mecobalamin: Tangbikang1:1group, Mecobalamin:Tangbikang1:2group, Mecobalamin:Tangbikang1:8group.
Compared with blank group,the contents of sVCAM-1, TNF-a. P38mitogen activated protein kinase and phosphorylated P38mitogen activated protein kinase were significantly risen, compared with50mM model group, the contents of sVCAM-1, TNF-a, P38mitogen activated protein kinase and phosphorylated P38mitogen activated protein kinase were significantly reduced in Mecobalamin:Tangbikanggroups.
[Conclusion]
Clinical trial
Chinese herbal compound Tangbikangcould improve of symptom, the nerve conductive velocity and the diabetic peripheral neuropathy integralsobviously, the total effective rate of the Tangbikang was91.14%.
1.vivo experiments:
1.1Chinese herbal compound Tangbikangcould improveblood glucose, body weight and blood lipid of STZ-DM rats; and reduce the content of non-esterified fatty acid in DPN rats serum; improvesciatic nerve conduction velocity of diabetic peripheral neuropathy rats, and it showed dose and time dependent.
1.2Chinese herbal compound Tangbikang could protect the morphology ofsciatic nervein DPN rats, and repair its sciatic nerve myelin sheath and neuraxon.
1.3Chinese herbal compound Tangbikang could rise the expression of FINS and NO in serum of DPN rats, reduce the expression of ET in plasma, these may be one of the mechanism of Tangbikang prevention and cure DPN.
1.4Chinese herbal compound Tangbikang could rise the expression of P-EP in plasma of DPN rats, these may be one of the mechanism of Tangbikangneuroprotection and abirritation of DPN.
1.5Chinese herbal compound Tangbikang could rise the expression of NGF, BDNF and NT-3protein and gene of sciatic nerve in DPN rats, reduce the expression of VEGF protein and gene of sciatic nerve in DPN rats, these may be one of the effective targets of Tangbikang prevention and cure DPN.
2.vitro experiment
2.1Tangbikang could proliferative activity of schwann cells in high sugar cultivation environment, Tangbikang is more effective then mecobalamin, Chinese herbal compound Tangbikangcould promoteproliferative activity of the rat sciatic nerve schwann cells,these may be one of the mechanism of Tangbikang neuroprotection and abirritation of DPN.
2.2Tangbikang containing serum could reduce the expression of p38MAPK and activate the expression of p-p38MAPK protein of the rat sciatic nerve schwann cells in high sugar cultivation environment, and reduce the content of TNF-a protein in the rat sciatic nerve schwann cells supernatant, these may be one of the effective targets of Tangbikang neuroprotection and abirritation of DPN.
2.3Tangbikang containing serum could reduce the content of sVCAM-1in the rat sciatic nerve schwann cells supernatant, this may be one of the effective targets of Tangbikang neuroprotection of DPN.
糖尿病周围神经病变(Diabetic peripheral neuropathy,DPN)是糖尿病(Diabetes mellitus, DM)常见并发症之一,临床上常常累及DPN患者的感觉神经及植物神经,使之产生刺痛、麻木甚至导致运动及神经功能障碍,发病率较高,严重危害患者的身体健康,是糖尿病病人致残的首要因素。DPN发病机制十分复杂,非单一因素所致,尚未完全阐明,造成西医对其治疗存在一定的局限性和有效性；中医药对DPN具有多手段、多途径、多靶点整体治疗优势和明显疗效。导师刘铜华教授经过多年的临床研究,认为本病主要病机为“气阴不足,毒瘀神络”,并在国内外首次提出“益气养阴、解毒化瘀通络”的新治疗原则。本课题在前期研究基础上,通过实验及临床研究,进一步探讨中药复方糖痹康对DPN神经保护机制及作用靶点,为临床推广应用提供理论依据。
[研究目的]
临床研究采用自身前后对照方法,客观评价临床有效复方中药糖痹康治疗糖尿病周围神经病变的临床有效性及安全性；实验研究通过动物及细胞模型,从分子水平探讨糖痹康作用机制。
[研究方法]
临床研究采用自身前后对照,观察中药复方糖痹康对35例DPN患者的临床疗效。在基础治疗(如血糖、血压、血脂等)的基础上,给予35例DPN病人口服糖痹康配方颗粒,治疗8周后,对病人的各项指标(如：中医证候、实验室检查及肌电图)进行客观评价。
实验研究
1整体实验
采用高脂饲料和小剂量链脲佐菌素诱发2型糖尿病大鼠动物模型,不同剂量的糖痹康灌胃,并与弥可保对照,每4周检测体重、空腹血糖和坐骨神经传导速度；16周后,光镜观察各组大鼠坐骨神经病理变化、电镜观察坐骨神经超微结构；采用酶法测定TC、 TG;采用免疫比浊法测定HDL-C、LDL-C;放射免疫法检测大鼠血浆β-EP、ET、FINS水平；铜试纸显色法检测大鼠血清NEFA、NO水平；免疫组织化学法和western blot检测坐骨神经NGF、BDNF、NT-3、VEGF蛋白表达；实时荧光定量RT-PCR检测NGF、BDNF. NT-3、VEGF mRNA表达。
2细胞实验
通过雪旺细胞株,建立高糖环境下大鼠雪旺细胞的细胞模型；用不同剂量的含药血清和正常血清培养基刺激24h、48h、72h和96h后,MTT法检测高糖环境下不同剂量的糖痹康含药血清对大鼠细胞增殖的影响；并用不同剂量的含药血清和正常血清培养基刺激48h后,采用放免法检测细胞上清中TNF-α的含量；ELISA法检测细胞上清中sVCAM-1的含量,Western blot法检测大鼠雪旺细胞P38和P-P38的表达。
[研究结果]
临床研究糖痹康治疗前后受试对象的双侧胫运动神经(MCv)、感觉神经(SCv)传导速度明显改善(P<0.05),且治疗前后安全性指标(血糖、糖化血红蛋白、血脂及血压)均在正常范围内,无显著性差异(P>0.05)同时未出现不良反应；总有效率达到91.14%。
实验研究：
1整体实验
与正常组比较,模型组体重均显著降低,血糖均显著升高,坐骨神经传导速率均显著降低,NO、β-EP、FINS、HDL-C、NGF的蛋白及mRNA、BDNF的蛋白及mRNA、NT-3的蛋白及mRNA的含量均显著降低,ET、TG、TC、LDL-C、NEFA、VEGF的蛋白及mRNA的含量均显著升高。与模型组比较,糖痹康及弥可保组体重均显著升高,血糖均显著降低,坐骨神经传导速率均显著升高,NO、β-EP、FINS、HDL-C、NGF的蛋白及mRNA、BDNF的蛋白及nRNA、NT-3的蛋白及mRNA的含量均显著升高,ET、TG、 TC、LDL-C、NEFA、VEGF的蛋白及nRNA的含量均显著降低。病理检测显示,正常组大鼠坐骨神经纤维结构紧密、分布均匀、排列整齐；模型组大鼠坐骨神经纤维排列疏松、间隙变大、多处发生变性及断裂；各给药组大鼠坐骨神经纤维的变性与断裂显著减少,纤维结构紧密、排列整齐,未见变性与断裂的发生,髓鞘变厚且着色均匀。电镜结果显示,正常组大鼠坐骨神经横切面髓鞘结构完整、致密、均匀；模型组大鼠坐骨神经横切面髓鞘的板层结构发生严重分离,各层间排列紊乱,出现大量空泡及裂隙；各给药组坐骨神经中空泡及裂隙均显著降低,但髓鞘仍未恢复板层状结构,线粒体及粗面内质网结构正常,出现结构完整的雪旺细胞。
2细胞实验
与空白组比较,24、48、72、96小时后,50MGLU与75MGLU组细胞增殖程度均显著降低,但50M GLU与75M GLU组间并无差异；与50mM高糖对照组比较,24、48小时后,弥可保及糖痹康1:1、1：2、1：8组均可显著增高细胞增殖能力。
与空白对照组比较,50mM高糖对照组的sVCAM-1、TNF-α、P38丝裂素活化蛋白激酶及磷酸化P38丝裂素活化蛋白激酶含量显著升高；与50mM高糖对照组比较,弥可保与糖痹康各剂量组上清中sVCAM-1、TNF-α、P38丝裂素活化蛋白激酶及磷酸化P38丝裂素活化蛋白激酶的含量显著降低。
[结论]
临床观察中药复方糖痹康可显著改善DPN患者的临床症状、提高神经传导速度、显著降低国际公认糖尿病周围神经病变积分并且总有效率达到91.14%。
实验研究
1整体实验：
(1)中药复方糖痹康能改善STZ-DM大鼠血糖、体重及血脂；降低DPN大鼠血清游离脂肪酸水平；改善糖尿病周围神经病变大鼠坐骨神经传导速度且存在剂量与用药时间依赖关系；
(2)中药复方糖痹康对DPN大鼠坐骨神经的形态具有保护作用以及对其坐骨神经髓鞘、轴索等具有修复作用；
(3)中药复方糖痹康能上调DPN大鼠FINS的表达、血清中NO的表达及下调血浆中ET的表达,这些可能是其防治DPN的机制之一；
(4)中药复方糖痹康能显著上调DPN大鼠血浆中p-EP的表达,这可能是其对糖尿病周围神经病变的神经保护及镇痛作用的机制之一；
(5)中药复方糖痹康能显著上调DPN大鼠坐骨神经中NGF、BDNF、NT-3蛋白及基因表达,下调DPN大鼠坐骨神经中VEGF蛋白及基因表达,这些可能是其防治DPN的有效作用靶点之一。
2细胞实验：
(1)糖痹康组可明显改善高糖培养环境下,雪旺细胞增殖活性,糖痹康低剂量组优于西药(弥可保)组,其在高糖培养的环境下,中医复方糖痹康可促进大鼠坐骨神经雪旺细胞的增殖,可能是其防治DPN的机制之一；
(2)糖痹康含药血清可下调在高糖环境下大鼠坐骨神经雪旺细胞p38MAPK及其激活形式p-p38MAPK蛋白表达,及下调大鼠坐骨神经雪旺细胞上清中TNF-α的含量,可能是其DPN神经保护及镇痛作用靶点之一；
(3)糖痹康含药血清可下调大鼠坐骨神经雪旺细胞上清中sVCAM-1的含量,可能是其DPN神经保护作用靶点之一。
[Study background]
Diabetic peripheral neuropathy (Diabetic peripheral neuropathy, DPN) is a common complication of diabetes mellitus (DM). DPN often involves sensory nerve and plant nerve, causing tingling, numbness, and even lead to exercise and nerve dysfunction in clinical. With high rate of incidence, it damages to health seriously and leads primary diabetes to disability. The world health organization estimates that there will be about360million DM patients in the world by2030, most of who suffer type2diabetes mellitus DPN. The pathogenesis of DPN is very complex and have not been fully elucidated causing limitation to the western medicine for the treatment and effectiveness yet. Traditional Chinese medicine treating DPN has overall advantages and obvious curative effect for its various means and ways. In recent years, there are many useful researches about DPN disease name, pathogenesis, clinical syndrome differentiation and treatment. The holistie therapy of DPN using TCM has its advantages and obviously curative effect. Professor Tonghua Liu insist the pathogenesis of DPN were deficiency of qi yin and poison stuck the shen collateral and brings up the new therapy of nourishing yin and qi, detoxify, dispersing blood stasis and clear the collateral. This project discusses the nerve protection mechanisms and targets of Chinese herbal compound Tangbikang treating DPN on the basis of previous research, and provides clinical basis of clinical application.
[Objective]
To objective evaluation of clinical efficacy and safety of treatment of diabetic peripheral neuropathy by Chinese herbal compound Tangbikang, the clinical trials were adopted by self control.
[Methods]
Clinic trial
35DPN patients conforming to the diagnostic criteria, based on the basic treatment for blood pressure, blood glucose and blood lipid, were given Chinese herbal compound Tangbikang. After curing for8weeks, we measured some indicators, like TCM syndrome, laboratory examination and electromyography.
Experimental research
1.vivo experiments
The experimental diabetes mellitus rats model were induced by feeding high fat forage and injection streptozotocin. Tangbikang groups were given Tangbikang with different dose, Body weight, blood glucose and sciatic nerves conduction velocitywere detected in every4weeks. Rats unilateral sciatic nerve were cutting-up after16weeks, pathological change of rat sciatic nerve of each group was observed with the light microscope, ultrastructure of rat sciatic nerve was observed by electron microscopy; the TC and TG were determined by the enzyme analysis method, the HDL-C and LDL-Cwere determined by immunoturbidimetry method; the p-EP,ET and FINS levels of rat plasma were determined by radioimmunoassay; the NEFA and NO levels of rat serum weredetermined by the method of Cul test paper; the expressions of NGF, BDNF, NT-3and VEGFproteinof rat sciatic nerve were determined by immunohistochemical assay and western blot; the expressions of NGF, BDNF, NT-3,and VEGF mRNA were detected by real-time fluorescence quantification.
2.vitro experiment
schwann cell model was establish in high glucose environment from schwann cells lineage.The effect of different dose Tangbikangon the proliferation of rat epidermal cells was detect by MTT method after stimulate by drug serum of different dose and serum at24h,48h,72h and96h. The content of TNF-a in supernatants were determined by radioimmunoassay after stimulate by drug serum of different dose and serum at48h; the content of sVCAM-1in supernatants were determined byELISA method; the expressions of schwann cell P38and P-P38were detected by Western blot method.
[Results]
Clinical trial
After the treatment byTangbikang, the conduction velocitiesof MCv and SCvwas better than before, the difference was significant (P<0.05).Security Indexincludingblood glucose, glycosylated hemoglobin, blood lipid and blood pressurewith normal limits, the difference was insignificant (P>0.05), and there were no obvious side effects has been found during the treatment; the total effective rate of the Tangbikang was91.14%.
Experimental research
1.vivo experiments
Compared with normal group, model group weight was significantly reduced, the blood glucose was significantlyrisen, sciatic nerves conduction velocity were significantly reduced, the content of NO,β-EP, FINS,HDL-C, protein and mRNA of NGF, protein and mRNA of BDNF and protein and mRNA of NT-3were significantly risen; the content of ET, TG, TC、LDL-C、NEFA、protein and mRNA of VEGF were significantly reduced. Compared with model group, the rats body weight with different doses of Tangbikang were significantly increased; the content of NO,β-EP HDL-C,FINS, protein and mRNA of NGF, protein and mRNA of BDNF and protein and mRNA of NT-3were significantly reduced; the content of ET、TG、TC、LDL-C、NEFA、protein and mRNA of VEGF were significantly risen. The pathological results showed that sciatic nervefiber of normal group was hard-packed, homogeneous distribution and in alignment; and looselyarranged, larger gap and degeneration and fracture in multiple places of model group; degeneration and fracture of sciatic nerve was significantly reduced in Tangbikang group, it was hard-packed, homogeneous distribution and in alignment, but has degeneration and fracture insome places, the myelin sheath was thickened and even colouring. Electron microscopy (sem) results showed that the sciatic nervemyelin sheath was structural integrity, densification and well-distributed in normal group, the sciatic nervemyelin sheath was serious separation of lamellar structure, a disordered arrangement between each layer and a large number of vacuoles and gaps were in control group, the vacuoles and gaps of sciatic nerve were significantly reduced in Tangbikang group, but the lamellar structure was also abnormal, the structures of mitochondria and rough endoplasmic reticulum were in normality, structural integrityschwann cell was observed.
2.vitro experiment
Compared with blank group,50M GLU and75M GLU groups, the degree of cell proliferation was significantly reduced after24h,48h,72h and96h, but there were no significantly difference between50M GLU and75M GLU group. Compared with50mM model group, the degree of cell proliferation wassignificantly risenin Mecobalamin: Tangbikang1:1group, Mecobalamin:Tangbikang1:2group, Mecobalamin:Tangbikang1:8group.
Compared with blank group,the contents of sVCAM-1, TNF-a. P38mitogen activated protein kinase and phosphorylated P38mitogen activated protein kinase were significantly risen, compared with50mM model group, the contents of sVCAM-1, TNF-a, P38mitogen activated protein kinase and phosphorylated P38mitogen activated protein kinase were significantly reduced in Mecobalamin:Tangbikanggroups.
[Conclusion]
Clinical trial
Chinese herbal compound Tangbikangcould improve of symptom, the nerve conductive velocity and the diabetic peripheral neuropathy integralsobviously, the total effective rate of the Tangbikang was91.14%.
1.vivo experiments:
1.1Chinese herbal compound Tangbikangcould improveblood glucose, body weight and blood lipid of STZ-DM rats; and reduce the content of non-esterified fatty acid in DPN rats serum; improvesciatic nerve conduction velocity of diabetic peripheral neuropathy rats, and it showed dose and time dependent.
1.2Chinese herbal compound Tangbikang could protect the morphology ofsciatic nervein DPN rats, and repair its sciatic nerve myelin sheath and neuraxon.
1.3Chinese herbal compound Tangbikang could rise the expression of FINS and NO in serum of DPN rats, reduce the expression of ET in plasma, these may be one of the mechanism of Tangbikang prevention and cure DPN.
1.4Chinese herbal compound Tangbikang could rise the expression of P-EP in plasma of DPN rats, these may be one of the mechanism of Tangbikangneuroprotection and abirritation of DPN.
1.5Chinese herbal compound Tangbikang could rise the expression of NGF, BDNF and NT-3protein and gene of sciatic nerve in DPN rats, reduce the expression of VEGF protein and gene of sciatic nerve in DPN rats, these may be one of the effective targets of Tangbikang prevention and cure DPN.
2.vitro experiment
2.1Tangbikang could proliferative activity of schwann cells in high sugar cultivation environment, Tangbikang is more effective then mecobalamin, Chinese herbal compound Tangbikangcould promoteproliferative activity of the rat sciatic nerve schwann cells,these may be one of the mechanism of Tangbikang neuroprotection and abirritation of DPN.
2.2Tangbikang containing serum could reduce the expression of p38MAPK and activate the expression of p-p38MAPK protein of the rat sciatic nerve schwann cells in high sugar cultivation environment, and reduce the content of TNF-a protein in the rat sciatic nerve schwann cells supernatant, these may be one of the effective targets of Tangbikang neuroprotection and abirritation of DPN.
2.3Tangbikang containing serum could reduce the content of sVCAM-1in the rat sciatic nerve schwann cells supernatant, this may be one of the effective targets of Tangbikang neuroprotection of DPN.
引文
[1]Yagihashi S,Pathology of diabetic neuropathy,a review from the up dated literature of the last 10 years[J]. Nippon Rinsho,2002,60 suppl 10:204
[2]Cameron NE,Eaton SE, Cotter MA, etal. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropahy[J].Diabetologia,2001,44(11):1973-1988
[3]曲秋菊,冯立群.血管活性因子改变糖尿病周围神经病微血管内皮损伤机制[J].国神经病学神经外科学杂志,2010,37(1)：53-54
[4]郭蔚莹,刘艳,朱丹.二型糖尿病合并周围神经病变内皮素及一氧化氮水平监测[J].中国实验诊断学,2005,9(3)：413-414
[5]王殿彬,陈汝贤,李建勇.糖尿病患者微血管病变与血小板机能[J].江苏医药,1994,20：121
[6]Wang Y,Schmeichel AM,Lida H,et al.Ischemia reperfusion injury causes oxidative stress and apoptosis of schwann cell Antioxid Redox signal[J].2005,7:1513-1520
[7]Purves T,Middlemas A,Agthongs,et al.A role form itogen activated protein kinases in the etiology of diabetic neuropathy[J].FASEB J,2001,15(13):2508-2514
[8]Senftleben U,Karin M.The IKK/NF-κB pathway [J]. Crit Care Med,2002,30(1 suppl): s18-s26
[9]丁俊,章秋,李芳,楚能武,鲁云霞.二甲双胍对2型糖尿病大鼠肝脏JNK表达的影响[J].安徽医科大学学报,2010,45(3)：334-337
[10]PahlHl.Actiators and target genes of Rel/NF-κB transcription factors[J].Oncogen.1999,18(49):6853-66
[11]Brownlee M.Biochemistry and molecular cell biology of diabetic complications[J]. Nature,2001,414(5):813-820
[12]Rownlee M.The pathobiology of diabetic complications a unifying mechanism [J]. Diabetes,2005,54(6):1615-1625
[13]Fukunaga M,Miyata S,Liu BF,et al.Methylglyoxal induces apoptosis through activation of P38MAPK in rat schwann cells[J]. Biochem Biophy Res Commun 2004, 320(3):689-695
[14]Schmeichel AM,Schmelzer JD,Low PA.Oxidative injury and apotosis of dorsal root ganglion neurons in chronic experimental diabetic neuropathy[J].Diabetes,2003,5(1):165-171
[15]Koh DW,Dawson TM,Dawson VL.Mediation of cell death by poly(ADP-ribose) polymerase-1[J]. Pharmacol Res,2005,52(l):5-14
[16]Pacher P,Szabo C.Role of poly(ADP-ribose)polymerase-1(PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors[J]. Cardiovasc Drug Rev,2007,25(3):235-260
[17]Yu SW,Wang H,Poitras MF,et al.Mediation of poly(ADP-ribose)polymerase-1 dependent cell death by apoptosis inducing factor[J].Science,2002,297(5579):259-261
[18]Dieckmann A, Kriebel M, Andriambeloson E, Ziegler D and Elmlinger M. Treatment with ActoveginR improves sensory nerve function and pathology in streptozotocin-diabetic rats via mechanisms involving inhibition of PARP activation[J].Exp Clin Endocrinol Diabetes,2012,120:132-138
[19]NiWa T.Dialysisrelated amyloidosis:pathogenesis focusing on AGE modif-ication[J].Semin Dial,2001,14(2):123-126
[20]King RHM.The role of glycation in the pathogenesis of diabetic polyneuropathy[J].J Clin pathol Mol Pathol,2001,54(6):400-408
[21]陆帮超,王坚.晚期糖基化终产物及其受体在糖尿病周围神经病变中的作用[J].中国神经免疫学和神经病学杂志,2007,14(6)：367-369
[22]Vincent AM,Perrone L, Sullivan KA,et al.Receptor for advanced glycation end productor activation injures primary sensory neurons via oxidative stress[J].Endocrinology,2007,148(2):548-558
[23]Ann Ms,Shi DYJean Lue,et al.Activation of receptor for advances Glycation End products[J].Circulation Research,1999,84:489-497
[24]Schmidt AM, et al.RAGE:a noval cellular receptor for advanced glycation end products[J].Diabetes,1996,45(suppl3):77
[25]Cellek S,Qu W,Schmidt AM,et al.Synergistic action of advanced glycation end products and endogenous nitric oxide leads to neuronal apoptosis in vitro:a new insight into selective neurergic neuropathy in diabetes[J].Diabetologia 2004,47(2):331-339
[26]Sina AA,Suginoto K.Experinental diabetic neuropathy: an up date[J].Diabetologia,1999,42(7):773
[27]Kubo E,Urakami T,Fatma N,et al. Polyri pathway-dependent osmotic and oxidative stresses in aldose reductase mediated apoptosis in human lens epithelial cells:role of A0P2[J].Biochem Biophys Res Commun,2004,314(4):1050-1056
[28]Michael B.Biochemistry and Molecular cell biology of diabetic complications[J].Nature,2001,414(6865):813-820
[29]Vinik AI.Diabetic neuropathy:pathogenesis and therapy[J].Am JM ed,1999,30: 107(2B):175
[30]Cosetino F,Eto M,De paolis p,et al.High glucose causes upregulation of cyclooxygenase-2 and alters prostanoid profile in human endothelial cells:role of protein kinase C and reactive oxygen species[J].Circulation 2003,107(7):1017-1023
[31]A Nitta,R Murai,N Suzuki,et al.Diabetic neuropathies in brain are induced by deficiency of BDNF[J].Neurotoxicology and Teratology,2002,24:695-701
[32]Quattrini C, Jeziorska M, Boulton AJ, et al. Reduced vascular endothelial growth factor expression and intra-epidermal nerve fiber loss in human diabetic neuropathy[J].Diabetes Care.2008,31 (1):140-145
[33]刘京生,孙正义,王宏沛.白介素-1和神经生长因子对周围神经再生的影响[J].中国临床康复,2002,6(18)：69-61
[34]苏会璇.糖尿病周围神经病变的发病机制[J]Clin Neurol.Oclober,2003,16(5)：314
[35]高志峰,冯艺,鞠辉,杨拨弦.神经生长因子在糖尿病神经病理性疼痛大鼠脊髓和背根神经节中的表达[J].临床麻醉学杂志,2009,25(2)：147-150
[36]Dyck PJ,Peroulka S,Rusk C,et al.Intradermal recombinant human nerve growth factor induces pressure allodynia and lowered heat-pain threshold in human[J].Neurology,1997,48:501
[37]Sullivan KA, Kim B, Feldman EL. Insulin-like growth factors in the peripheral nervous system[J].Endocrinology,2008,149(12):5963
[38]徐静,张春虹,王俊宏,王学良,袁晓红,张喜民.胰岛素样生长因子-Ⅰ与糖尿病下肢血管病变的关系[J].西安交通大学学报：医学版,2007,28(4)：434-450
[39]Delva P,Pastori C,Montesi G.Intralymphocyte free magnesium and insulin tolerance test in a group of essential hypertensive patients [J]. Life Science,1998,63:14-15
[40]Sayers NM,Besw ick LJ,Middlem as A,et al.Neurotrophin-3prevents the proximal accumulation of neurofilament proteins in sensory neurons of streptozocin-induced diabetic rats[J].Diabetes,2003,52(9):23-32
[41]熊丽丽,陈泽奇,黄娟,傅擎宇.加味补肝汤对糖尿病大鼠坐骨神经脑源性神经生长因子表达的影响[J].中国中医药信息杂志,2008,15(12)：42-44
[1]秦玖刚.补肾活血汤治疗糖尿病周围神经病变68例临床观察[J].四川中医,2007,25(6)：48-49
[2]赵丹.当归四逆汤治疗糖尿病周围神经病变30例[J].吉林中医药,2006,26(4)：28
[3]李谷松.糖尿病并发症证治[J].新中医,1990,22(9)：13
[4]张兰,陈盛业.DPN"洛损”中医辩证属性的研究[J].中国中医药现代远程教育,2008,6(8)：886-888
[5]全小林,倪青,宋军.糖尿病中医防治指南解读[M].北京：中国中医药出版社,2009,110-129
[6]陈谦.吕仁和治疗治疗糖尿病周围神经病变经验[J].中国医药学报,2002,17(1)：35
[7]赵秉祥.从气血论治糖尿病周围神经病变[J].辽宁中医杂志,2004,31(12)：995-996
[8]胡晓玲,张卫华.从脾胃本虚、痰瘀毒标论述糖尿病周围神经病变[J].新疆中医药,2006,24(1)：1-2
[9]詹继红.糖尿病周围神经病变从肝论治[J].贵阳中医学院学报,1999,21(4)：34-35
[10]吴兆利.糖尿病周围神经病变从血瘀论治[J].中国中西医基础医学杂志,2002,8(3)：23
[11]张兰,于世家.糖尿病周围神经病变瘀血洛损病机探微[J].新中医,2002,34(10)：6
[12]孙振武.糖尿病周围神经病变辩治例析[J].实用中医内科杂志,2009,23(6)：71-72
[13]于秀振.吕仁和教授辩治糖尿病周围神经病变经验[J].中级医刊,1997,32(12)：42-43
[14]李国建.辨证论治治疗糖尿病周围神经病变42例分析[J].中国实用神经疾病杂志,2008,11(12)：88-89
[15]刘春红,范冠杰,唐咸玉.补阳还五汤治疗糖尿病周围神经病变42例临床疗效观察[J].四川中医,2003,21(10)：31-32
[16]苏根.补阳还五汤治疗糖尿病周围神经病变临床观察[J].河南中医,2004,24(4)：66-67
[17]周晖,补阳还五汤合六味地黄汤治疗糖尿病周围神经病变[J].河南中医,2003,23(1)：29
[18]杨丽莉.黄芪桂枝五物汤加减治疗糖尿病周围神经病变40例[J].河南中医中医,2013,33(6)：853-854
[19]张烨雄,王珺洁.黄芪桂枝五物汤配合西药治疗糖尿病周围神经病变疗效观察[J].陕西中医,2013,34(4)：414-415
[20]王祥.黄茂桂枝五物汤联合甲钻胺治疗糖尿病周围神经病变随机平行对照研究[J].实用中医内科杂志,2013,27(7)：123-125
[21]盛庆祥.加味黄芪桂枝五物汤治疗糖尿病周围神经病变38例[J].湖南中医杂志, 2008,24(6)：451
[22]雷国大.血塞通胶囊治疗糖尿病周围神经病变的临床观察[J].中西医结合心脑血管病杂志,2006,4(6)：537-538
[23]蔡瑞玉.血塞通联合维生素B12治疗糖尿病周围神经病变临床疗效观察[J].实用糖尿病杂志,2013,9(6)：22-23
[24]吕贵德.益肾通络胶囊治疗糖尿病周围神经病变66例[J].湖北中医杂志,2004,24(6)：33
[25]吴兆利.糖未宁煎剂对DPN血瘀证患者血液流变学的影响[J].辽宁中医杂志,2002,29(4)：207
[26]王丽伟,李俊成.川芎注射液和氟桂利嗪治疗糖尿病周围神经病变[J].医药论坛杂志,2009,(02)：88-89
[27]樊永方,翁孝刚,窦敬芳.川芎嗪治疗糖尿病周围神经病变的临床观察[J].中国中西医结合杂志,1999,19(9)：550-551
[28]于斌,姜喆.盐酸川芎嗪治疗糖尿病周围神经病变疗效观察[J].长春中医药大学学报,2007,23(1)：39
[29]赵彩霞.足浴疗法治疗糖尿病周围神经病变74例临床观察[J].河北中医药学报,2001,16(1)：25
[30]王晓娜,董永利.熏洗方辅助治疗糖尿病周围神经病变的观察与护理[J].实用中医内科杂志,2007,21(5)：80
[31]赵迪.中药足浴治疗糖尿病周围神经病变疗效观察[J].辽宁中医杂志,2007,34(4)：452-453
[32]玉红,陈泽奇,叶仁群,贺钰磊.加味补肝汤对糖尿病周围神经病变大鼠背根节P38丝裂素活化蛋白激酶表达的干预作用[J].中国临床康复,2006,10(7)：67
[33]叶仁群,陈泽奇,李玉红,贺钰磊,林国彬,谢嘉嘉.加味补肝汤对实验性糖尿病大鼠坐骨神经NGF表达的影响[J].北京中医药大学学报,2007,30(2)：90-93
[34]叶仁群,陈泽奇,熊丽丽,李玉红,贺钰磊,林国彬,凌江红,申定珠.加味补肝汤对糖尿病大鼠背根节细胞凋亡的影响[J].湖南中医药大学学报,2008,28(5)：44-47
[35]熊丽丽,陈泽奇,黄娟,傅擎宇.加味补肝汤对实验性糖尿病大鼠坐骨神经BDNF表达的干预作用[J].实用预防医学,2008,15(6)：1683-1686
[36]傅擎宇,熊丽丽,陈泽奇,黄娟,戴幸平.加味补肝汤对糖尿病周围神经病变大鼠坐骨神经VEGF表达的干预作用[J].中国中医药科技,2008,15(6)：413-415
[37]傅擎宇,熊丽丽,陈泽奇,黄娟.加味补肝汤对实验性糖尿病大鼠坐骨神经PKC-βⅡ表达的影响[J].湖南中医药大学学报,2009,29(1)：29-32
[38]黄文智,梁晓春,王普艳,赵丽,李伯武,张彦东.筋脉通对实验性糖尿病坐骨神经AGEs及其受体表达的影响[J].中华中医药杂志,2011,26(4)：806-809
[39]屈岭,梁晓春,吴群励,孙连庆,赵丽,陈锡萍,钟定荣.筋脉通对糖尿病大鼠周围神经组织神经生长因子表达的影响[J].中国中药杂志,2008,33(21)：2539
[40]孙连庆,梁晓春,张宏,吴群励,屈岭,赵丽,顾蓓.中药筋脉通对高糖培养雪旺细胞增殖及NGF表达的影响[J].中华中医药杂志,2009,24(8)：1019-1022
[41]吴群励,梁晓春,孙连庆,屈岭,赵丽,王普艳.筋脉通对糖尿病大鼠周围神经组织睫状神经营养因子表达的影响[J].全国中医药中青年科技创新与成果展示论坛论文集,2011,中医药基础研究：319-324
[42]吴群励,张宏,朴元林,屈岭,孙连庆,王普艳,石玥,高云周,梁晓春.筋脉通胶囊通过增强背根神经节Nrf2和HO-1的表达改善糖尿病大鼠的周围神经痛[J].基础医学与临床,2014,34(2)：179-184
[43]吴群励,梁晓春,高云周,屈岭,孙连庆,赵丽,石玥.筋脉通胶囊对糖尿病大鼠坐骨神经神经生长因子受体p75NTR及TrkA表达的影响[J].北京中医,2013,32(7)：548-552
[44]吴群励,梁晓春,张宏,屈岭,孙连庆,赵丽,顾蓓.中药筋脉通含药血清对高糖培养雪旺细胞NF-KB表达的影响[J].世界中西医结合杂志,2011,6(6)：478-481
[45]李柏武,梁晓春,王普艳,赵丽,黄文智.筋脉通对糖尿病大鼠坐骨神经NADPH氧化酶P22-Phox亚基表达的影响[J].医学研究杂志,2011,40(5)：43-46
[46]张效科,段玉红,孟凡冰.复方中药干预糖尿病周围神经病早期病变的机理研究[J].陕西中医,2008,29(6)：755-756
[47]张效科,孟凡冰,段玉红.消渴通痹颗粒防治糖尿病周围神经病病变大鼠IL-1β、TNF-a及CD54的影响[J].陕西医学杂志中医,2008,37(6)：1136-1137
[48]王嘉新,何国芬,贡克明,张辉.槲皮素对糖尿病大鼠周围神经病变的保护作用[J].中国药理与毒理学杂志,1997,11(3)：233
[49]王启慧.糖尿病单味中药作用机理研究概述[J].安徽中医学院学报,1999,(4)：58
[50]马松涛,王秋林,张效科.桑白皮提取物对实验性糖尿病神经病变的保护作用[J].中华中医药杂志,2006,21(12)：776-777
[51]马松涛,张效科.桑白皮提取物对糖尿病大鼠神经生长因子、碱性髓鞘蛋白表达的影响[J].中国中医基础医学杂志,2007,13(10)：760-761
[52]马松涛.桑白皮提取物对防治糖尿病大鼠神经病变实验研究[J].中药药理与临床,2006,22(34)：117-118
[53]马松涛,王秋林,张效科.桑白皮提取物对糖尿病大鼠坐骨神经传导速度及生化功能的影响[J].中国药房,2007,18(3)：174-176
[54]游龙,王耕.影响血糖升降的65种中药[J].中国中医药信息杂志,2007,7(5)：32-33
[55]华文进,卜平.糖尿病周围神经病变的中西医结合治疗进展[J].医学研究生学报,2008,21(11)：1219-1221
[56]逢紫千,王朝辉,朱丹,叶玉琴.早期针刺干预补对糖尿病周围神经病变大鼠坐骨神经电生理的影响[J].吉林中医药,2010,30(9)：808-810
[57]董彦敏,李慧林,倪青,马慧芳,睢明河.针刺对糖尿病周围神经病变治疗作用的实验研究[J].北京中医药大学学报,2006,13(2)：7-10
[58]郑敏,张秋娟,东红升,施茵,杨强.针刺结合治疗糖尿病周围神经病变大鼠的实验研究[J].时珍国医国药,2009,20(8)：2006-2008
[59]向婷,王华.“双固一通”灸法对DPN大鼠坐骨神经传导速度和超微结构影响的研究[J].辽宁中医药大学学报,2010,12(5)：242-244
[60]孙远征,王伟华,毛翔.温针对大鼠糖尿病周围神经病变坐骨神经传导速度及MDA、SOD、TAOC的作用[J].上海针灸杂志,2011,30(2)：134-136
[61]苏纪武,毛翔,孙远征,王伟华.温针灸对糖尿病大鼠坐骨神经AGEsmRNA、 RAGEmRNA表达的影响[J].针灸临床杂志,2010,26(2)：51-54
[1]Ziegler, D.& A. Bierhaus.2007. Therapie der diabetischen Neuropathie[J]. Dtsch. Med.Wochenschr.132:11-16
[2]Agroff, C.E, B.E. Cole, D.A. Fishbain, et al.2006. Diabetic peripheral neuropathic pain: clinical and quality-oflife issues[J]. Mayo Clin. Proc.81(4 Suppl):S3-S11
[3]许曼音,陆广华,陈名道.糖尿病学[M].上海：上海科学技术出版社,2003：423-434
[4]朱禧星.现代糖尿病学[M].上海科学技术出版社,2000,11：333-340
[5]吕仁和,张法荣,高彦彬.消渴病(糖尿病)的分期辨证与疗效评价标准[J].中国医药报,1993,8(3)：50-56
[6]Kawai T, Takei I, Tokui M, Funae O, Miyamoto K, Tabata M, Hirata T, Saruta T,Shimada A, Itoh H. Effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy in patients with type 2 diabetes, in relation to suppression of N(ε)-carboxymethyl lysine[J]. J Diabetes Complications.2010,24(6):424-432
[7]Andrew J, M Boulton, FRCP, Arthur I, Vinik, et al. Diabetic Neuropathies:A statement by the American Diabetes Association[J].Diabetes Care,2005,28:956-962
[8]Argoff CE, Cole BE, Fishbain DA, Irving GA. Diabetic peripheral neuropathic pain: clinical and quality-of-life issues[J].Mayo Clin Proc,2006,81:S3-11
[9]Leinninger GM, Vincent AM, Feldman EL. The role of growth factors in diabetic peripheral neuropathy [J]. J Periph Nerv Syst,2004,9:26-53
[10]Brownlee M. The pathobiology of diabetic complications:a unifying mechanism[J]. Diabetes,2005,54 (6):1615-1625
[11]Schmeichel AM, Schmelzer JD, Low PA. Oxidative injury and apoptosis of dorsal root ganglion neurons in chronic experimental diabetic neuropathy [J].Diabetes,2003,52 (1):165-171
[12]Feldman EL. Oxidative stress and diabetic neuropathy:a new understanding of an old problem[J].J Clin Invest,2003,111(4):431-433
[13]陈谦.吕仁和治疗治疗糖尿病周围神经病变经验[J].中国医药学报,2002,17(1)：35
[14]赵秉祥.从气血论治糖尿病周围神经病变[J].辽宁中医杂志,2004,31(12)：995-996
[15]胡晓玲,张卫华.从脾胃本虚、痰瘀毒标论述糖尿病周围神经病变[J].新疆中医药,2006,24(1)：1-2
[16]张兰,于世家.糖尿病周围神经病变瘀血洛损病机探微[J].新中医,2002,34(10)：6
[17]游龙,王耕.影响血糖升降的65种中药[J].中国中医药信息杂志,2000,7(5)；32-33
[18]范征吟,叶信莉.自拟“糖宁Ⅲ号合剂”治疗Ⅱ型糖尿病的研究[J].上海中医药杂志,2000,34(5)：14-16
[19]韩喻美.Fura-2荧光测定中药有效成分对神经细胞内Ca2+浓度的变化[J].江西医学院学报,1996,36(4)：11
[20]周中和,曲方,何祥.局部应用重组水蛭素对大鼠脑出血神经细胞凋亡的干预作用阴.临床神经病学杂志,2006,19(4)：304-306
[1]Wild S, Roglic G, Green A, Sicree R, King H: Global prevalence of diabetes:estimates for the year 2000 and projections for 2030[J]. Diabetes Care,2004,27:1047-1053
[2]王佳,刘铜华.糖痹康对糖尿病大鼠血清神经性因子及坐骨神经神经性因子基因表达的影响[J].中国实验方剂学杂志,2010,16(6)：160-163
[3]王佳,刘铜华.糖痹康对糖尿病周围神经病变大鼠坐骨神经传导速度的影响[J].中国中医基础医学杂志,2010,16(3)：209-211
[4]王佳,刘铜华.糖痹康对大鼠糖尿病周围神经病变氧化应激影响的实验研究[J].国际中医中药杂志,2010,10(4)：211-238
[5]穆晓红,刘铜华,秦灵灵,王磊,吴丽丽,李娟娥,孙文,张宏.从血液流变学和坐骨神经传导速度评价中药糖痹康对大鼠糖尿病周围神经病变的影响[J].中华中医药杂志,2012,27(2)：378-381
[6]吴晏,韩静,黄黎明,郭淑贞,王伟.高脂喂养合并小剂量链脲佐菌素建立2型糖尿病大鼠模型[J].中国实验动物学报,2012,20(2)：11-15
[1]Argoff C E,Cole B E,Fishbain D A,et al.Diabetic peripheral neuropathic pain:clinical and quality-of-life issues[J].Mayo Clin Proc,2006,81:3-11
[2]姚鸿萍,封卫毅,魏友霞,董海燕.大鼠坐骨神经传导速度测定的方法学考察[J].中国药房,2011,1(22)：18-20
[3]吴丙云,鲁珊珊,刘莹.糖尿病周围神经病分型及神经电生理检查研究进展[J].山东医药,2007,(17)：96-97
[4]杨廷强,朱瑾,李秀钧.大剂量甲钴胺治疗糖尿病周围神经病变疗效观察[J].华西医学,2007,22(1)：131
[5]魏立新,顾德新.甲钴胺联合血塞通治疗糖尿病周围神经病变的临床观察[J].中国医学创新,2011,8(7)：162-163
[6]Li ZG, Zhang W, Sima AAF. C2peptide prevents hippocampal apoptosis in type 1 diabetes[J]. Int Exp Diabetes Res,2002,3 (4):241-246
[7]Ji Woong Han, Min Young Sin, Young-sup Yoon. Cell Therapy for Diabetic Neuropathy Using Adult Stem or Progenitor Cells[J]. Diabetes Metab J,2013,7:91-105
[8]刘彩艳,魏健,徐栋.鲑鱼降钙片治疗糖尿病周围神经病变疼痛及p-内啡肽变化[J].实用医药杂志,2004,21(3)：201-204
[9]沈祥峰,柴可夫,杨明华.运脾和络颗粒对糖尿病周围神经病变大鼠血浆p-内啡肽的影响[J].中华中医药学刊,2011,29(1)：125-127
[10]曲秋菊,冯立群.血管活性因子改变糖尿病周围神经病微血管内皮损伤机制[J].国际神经病学神经外科学杂志,2010,37(1)：53-54
[11]郭蔚莹,刘艳,朱丹.二型糖尿病合并周围神经病变内皮素及一氧化氮水平监测[J].中国实验诊断学,2005,9(3)：413-414
[1]吴晏,韩静,黄黎明,郭淑贞,王伟.高脂喂养合并小剂量链脲佐菌素建立2型糖尿病大鼠模型[J].中国实验动物学报,2012,20(2)：11-15
[2]Mithieux G, Guignot L, Bordet JC, et al. Intrahepatic mecha-nisms underlying the effect of metformin in decreasing basal glu-cose production in rats fed a high-fat diet[J]. Diabetes,2002,51; 139-143
[3]Chan CB, De Leo D, Joseph JW, et al. Increased uncoupling protein-2 levels in P-cells are associated with impaired glucose-stimulated insulin secretion:mechanism of action[J]. Diabetes,2001,50; 1302-1310
[4]Reimer MK, Aher NB. Altered β-cell distribution of pdx-1 andGLUT-2 after a short-term challenge with a high-fat diet in C57BL/6J mice[J]. Diabetes,2002,51:S138-S143
[5]卜石,杨文英,王昕,刘雪莉,陈仕明,湛玉良.长期高脂饲养对大鼠葡萄糖刺激的胰岛素分泌的影响[J].中华内分泌代谢杂志,2003,19：25-28
[6]周中和,曲方,何祥.局部应用重组水蛭素对大鼠脑出血神经细胞凋亡的干预作用[J].临床神经病学杂志,2006,19(4)：304-306
[7]MC Garry D. Banting lecyure 2001:Dysregulation of fatty acid metabolism in the etiology of type2 diabete[J]. Diabetes,2002,51(1):7-18
[8]Costa J,Borges M,David C,et al.Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patient:meta-analysis of randomised controlled trials[J].2006,332:1115-24
[9]Yamakawa I, Kojima H, Terashima T, Katagi M, Oi J, Urabe H, Sanada M, Kawai H, Chan L, Yasuda H, et al. Inactivation of TNF-aameliorates diabetic neuropathy in mice[J]. Am J Physiol Endocrinol Metab,2011,301:E844-852
[10]Cameron VF, Gibson TM, Vangle MR, et al. Inhibitors of advanced glvcati on end products formation and neurovascular dysfunction in experimental diabetes[J]. Ann N Y Acad Sci,2005,1043:784-792
[11]Tesfaye S, Chaturvedi N, Eaton S E, et al. Vascular risk factors and diabetic neuropathy [J]. N Engl J Med,2005,352:341-350
[1]Vinik AI.Diabetic neuropathy:pathogenesis and therapy[J].Am JM ed,1999,30:107(2B):175
[2]Quattrini C, Jeziorska M, Boulton AJ, et al. Reduced vascular endothelial growth factor expression and intra-epidermal nerve fiber loss in human diabetic neuropathy [J]. Diabetes Care,2008,31(1):140-145
[3]苏会璇.糖尿病周围神经病变的发病机制[J].Clin Neurol.Oclober,2003,16(5):314
[4]Aauda H,Terada M,Maeda K,et al. Diabetic neuropathy and nerve regeneration[J]. Prog Neurobiol,2003,69(4):229
[5]刘京生,孙正义,王宏沛.白介素-1和神经生长因子对周围神经再生的影响[J].中国临床康复,2002,6(18)：26961
[6]高志峰,冯艺,鞠辉,杨拨贤.神经生长因子在糖尿病神经病理性疼痛大鼠脊髓和背根神经节中的表达[J].临床麻醉学杂志,2009,25(2)：147-150
[7]Dyck PJ,Peroulka S,Rusk C,et al.Intradermal recombinant human nerve growth factor induces pressure allodynia and lowered heat-pain threshold in human [J]. Neurology,1997,48:501
[1]Vinik AI.Diabetic neuropathy:pathogenesis and therapy[J].Am JM ed,1999,30:107(2B):175
[2]Qi S, Zhan RZ,Wu C, et al. The effects of thiopen tal and propofol on cell swelling induced by oxygen/glucose cell layer of rat hippocampal slicers[J].Anesth Analg,2002,94(3):655-660
[3]A Nitta, R Murai, N Suzuki, et al. Diabetic neuropathies in brain are induced by deficiency of BDNF[J].Neurotoxicology and Teratology,2002,24:695-701
[4]叶仁群,陈泽奇,李玉红,贺钰磊,林国彬,谢嘉嘉.加味补肝汤对糖尿病大鼠坐骨神经NGF表达的影响[J].北京中医药大学学报,2007,30(2)：90-94
[5]A Tsuchida,T Nonomura, M Ono-Kishino. Acute effects of brain-derived neurotrophic factor on energy expenditure in obese diabetic mice[J].Obesity,2001,25(9):1286-1293
[6]Tolwani RJ, Cosgaya JM, Varma S, Jacob R, Kuo LE, Shooter EM. BDNF overexpression produces a long-term increase in myelin formation in the peripheral nervous system[J]. Neurosci Res.2004,77:662-669
[7]熊丽丽,陈泽奇,黄娟,傅擎宇.加味补肝汤对糖尿病大鼠坐骨神经脑源性神经生长因子表达的影响[J].中国中医药信息杂志,2008,15(12)：42-44
[1]Vinik AI.Diabetic neuropathy: pathogenesis and therapy[J]. Am JM ed,1999,30: 107(2B):175
[2]Lim PA,Tow AM.Recovery and regeneration after spinal cord injury: a review and summary of recent literature[J]. Ann Acad Med Singapore,2007,36(1):49-57
[3]Dumont RJ,Verma S,Okonkwo DO, et al.Acute spinal cord injury,part Ⅱ:contemporary pharmacotherapy[J]. Clin Neuropharmacol,2001,24(5):265-79
[4]Reyes O,Soas I,Kuffler DP,Neuroprotection of spinal neuropns against blunt trauma and ischemia[J]. PR Healht Sci J,2003,22(3):277-86
[5]Kirshbium SC,Groah SL,McKinley WO,et al. Spinal cord injury medicine 1. Etiology classification and acute medical managemen[J].Areh Phys Med Rehabil,2002,83(3 Suppl):S50-57-S90-98
[6]Sekhon LS,Fehlings MG.Epidemiology,demographic,and pathophysiology of acute spinal cord injury[J].Spine,2001,26(24S):S2-12
[7]Buxton N.The military medicine management of missile injury to the spine:a review of the literature and proposal of guidelines[J]. RArmyMed Corps,2001,147(2):168-172
[8]Jacobs WB,Fehlings MG.The molecular basis of neural regenration neurosurgery[J]. Am JM ed,2003,53(4):943-948
[9]Qin Dx, Zou xl, Luow, et aL.Expression of some neurotrophins in the spinal motoneurons after cord hemisection in adult rats[J].Neurosci Lett,2006,410(3):222-227
[10]Li x-L,Zhang W,Zhou X, et al.Tempral changes in the expression of some neurotrophins in spinal cord transected adult rats[J].Neuropeptides,2007, April 23, Epub ahesd of print
[11]Sayers NM,Besw ick LJ,Middlem as A, et al. Neurotrophin-3prevents the proximal accumulation of neurofilament proteins in sensory neurons of streptozocin-induced diabetic rats[J]. Diabetes,2003,52(9):2372
[12]Bae Jin Kim, Hee Kyung Jin, Jae-Sung Bae. Bone Marrow-Derived Mesenchymal Stem Cells Improve the Functioning of Neurotrophic Factors in a Mouse Model of Diabetic Neuropathy[J]. Lab Anim Res,2011,27(2):171-176
[1]Vinik AI.Diabetic neuropathy:pathogenesis and therapy[J]. Am JM ed,1999,30: 107(2B):175
[2]Verheul HM, Pinedo HM. Vascular endothelial growth factor and its inhibitors[J]. Drugs Today,2003,39 Suppl C:81-93
[3]Sung JK, Koh JH, Lee MY, et al. Aldose reductase inhibitor ameliorates renal vascular endothelial growth factor expression in streptozotocin-induced diabetic rats[J]. Yonsei Med J,2010,51:385-391
[4]Quattrini C,Jeziorska M,Boulton AJ, et al. Reduced vascular endothelial growth factor expression and intra-epidermal nerve fiber loss in human diabetic neuropathy[J].Diabetes Care,2008,31:140-145
[5]Sondell M, Sundler F, Kanje M. Vascular endothelial growth factor is a neurotrophic factor which stimulates axonal outgroth through the flk-1 receptor[J]. Eur J Neurosci, 2000,12:4243-4254
[6]Hobson MI, Green CJ, Terenghi G. VEGF enhances intraneural angiogenesis and improves nerve regeneration after axotomy[J]. J Anat,2000,197:591-605
[7]Samii A, Unger W, Lange W. Vascular endo thelial grow th facto r in peripheral nerve and do rsal root ganglia in diabeticneuropathy in rats.[J]. Neuro sciL ett,1999,262:159-162
[8]王巍,于世家,谢映红.糖末宁颗粒对糖尿病周围神经病变大鼠坐骨神经血管内皮生长因子表达的影响[J].中华保健医学杂志,2012,14(2)：19-21
[1]Magnani P, Thomas TP, Tennekoon G, et al. Regulation of glucose transport in cultured Schwann cells[J]. J Peripher Nerv Syst,1998,3:28-36
[2]Scarpini E, Doronzo R, Baron P, et al. Phenotypic and proliferative properties of Schwann cells from nerves of diabetic patients[J]. Int J Clin Pharmacol Res,1992,12(5-6):211-215
[3]Ide C. Peripheral nerve rege neration[J]. Neurosci Res,1996,25:101-121
[4]Dubovy R Schwann cells and endoneurial extracellular matrix molecules as potential cues for sorting of regenerated axons:a review[J]. Anat Sci Int,2004,79:198-208
[5]Chen Zl,Yu Wm, Strickland S. Peripheral regeneration[J]. Amu Rev Neurosci,2007,30: 209-233
[6]王筠,张军平.中药血清药理学实验方法概述[J].天津中医药,2005,22(1)：86-88
[7]张宏,刘铜华.糖痹康对高糖损伤人脐静脉内皮细胞的保护作用[J].中华中医药期刊,2012,30(6)：1248-1251
[8]穆晓红.糖痹康干预糖尿病周围神经病变神经保护作用及机制研究,2011年博士后出站报告
[1]潘长玉译Joslin糖尿病学(14版)[M].北京：人民卫生出版社,2007： 988
[2]CobbMH.MAPkinasePathways [J]. ProgBioPhysMolBiol.1999,71(3-4):479-500
[3]JinSX,ZhuangZY,woolfCJ,etal.P38Mitogen-activated Protein kinase is activated After as Pinal nerve ligation in spinal cord microglia and dorsal root ganglion neurons and contributes to the generation of neuropathic pain[J]. Neurosci,2003,23(10):4017-4022
[4]Piao AG,Cho IH,Park CK.Activation of glia and microglial P38MAPK in medullary Dorsal horn contributes to tactile hyPersensitivity following trigeminal sensory nerve injury[J].Pain,2006,121(3):219-31
[5]Deleroix JD,Vallellu JS,Wu C,et al.NGF signaling in sensory neurons:evidence that early endosomes carry NGF retrograde signals [J]. Neuron,2003,39(1):69-84
[6]Schafers M,Svensson Cl,Sommer C,et al.Tumor necrosis factor-alPha induces mechanical Allodynia after sPinal nervel igation by activation of P38MAPK in Primary sensory neurons[J].Neurosei,2003,23(7):2517-2521
[7]Hall GC,Carroll D,parry D, McQuay HJ. Epidemiology and treatment of neuro-pathic Pain:the UK Primary care PersPeetive[J].Pain,2006,122:156-162
[8]Moalem G, Tracey DJ. Immune and inflammatory mechanisms in neuroPathic Pain[J]. Brain Res Rev,2006,51:240-264
[9]Bolin LM,Verity AN,silver JE,shooter EM, Abrams Js. Interleukin-6 produetion By Schwann cells and induction insciatic nerve injury[J]. Neuroehem,1995,64:850-858
[10]Shamash S,Reiehert F, Rotshenker S. The cytokine network of Wallerian degeneration:tumor necrosis factor-alPha,interleukin-lalPha,and inter-leukin-1 beta[J]. Neurosci,2002,22:3052-3060
[11]EmPI M,Renaud S,Erne B,Fuhr P,Straube A,Schaeren-Wiemers N,Steck AJ:TNF-alpha eXPression in Painful and nonPainful neuroPathies[J].Neurology,2001,56:1371-1377
[12]Schafers M,Svensson C1,Sommer C, Sorkin LS. Tumor necrosis factor alPha Induces mechanical allodynia after sPinal nerve ligation by activation of P38MAPK in Primary sensory neurons[J].Neurosci,2003,23:2517-2521
[13]Matsumoto K, Sera Y, Ueki Y, et al. Comparison of serum concentrations of soluble adhesion molecules in diabet ic microangiopathy and macroangiopathy[J]. Diabet Med, 2002,19:822-828
[14]王加林,赵亚平,周玮等.Ⅱ型糖尿病患者血清sICAM-1和sVCAM-1检测及其临床意义[J].免疫学杂志,1999,15：120-121
[15]杨虹,卢学勉,叶成夫,陈良苗.血清sVCAM-1和sICAM-1的变化与DPN的关系 [J].辽宁实用糖尿病杂志,2004,12(2)：19-20
[16]Yagihashi S,Pathology of diabetic neuropathy,a review from the up dated literature of the last 10 years[J]. Nippon Rinsho,2002,60suppl 12:200-204
[2]Cameron NE,Eaton SE, Cotter MA, etal. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropahy[J].Diabetologia,2001,44(11):1973-1988
[3]曲秋菊,冯立群.血管活性因子改变糖尿病周围神经病微血管内皮损伤机制[J].国神经病学神经外科学杂志,2010,37(1)：53-54
[4]郭蔚莹,刘艳,朱丹.二型糖尿病合并周围神经病变内皮素及一氧化氮水平监测[J].中国实验诊断学,2005,9(3)：413-414
[5]王殿彬,陈汝贤,李建勇.糖尿病患者微血管病变与血小板机能[J].江苏医药,1994,20：121
[6]Wang Y,Schmeichel AM,Lida H,et al.Ischemia reperfusion injury causes oxidative stress and apoptosis of schwann cell Antioxid Redox signal[J].2005,7:1513-1520
[7]Purves T,Middlemas A,Agthongs,et al.A role form itogen activated protein kinases in the etiology of diabetic neuropathy[J].FASEB J,2001,15(13):2508-2514
[8]Senftleben U,Karin M.The IKK/NF-κB pathway [J]. Crit Care Med,2002,30(1 suppl): s18-s26
[9]丁俊,章秋,李芳,楚能武,鲁云霞.二甲双胍对2型糖尿病大鼠肝脏JNK表达的影响[J].安徽医科大学学报,2010,45(3)：334-337
[10]PahlHl.Actiators and target genes of Rel/NF-κB transcription factors[J].Oncogen.1999,18(49):6853-66
[11]Brownlee M.Biochemistry and molecular cell biology of diabetic complications[J]. Nature,2001,414(5):813-820
[12]Rownlee M.The pathobiology of diabetic complications a unifying mechanism [J]. Diabetes,2005,54(6):1615-1625
[13]Fukunaga M,Miyata S,Liu BF,et al.Methylglyoxal induces apoptosis through activation of P38MAPK in rat schwann cells[J]. Biochem Biophy Res Commun 2004, 320(3):689-695
[14]Schmeichel AM,Schmelzer JD,Low PA.Oxidative injury and apotosis of dorsal root ganglion neurons in chronic experimental diabetic neuropathy[J].Diabetes,2003,5(1):165-171
[15]Koh DW,Dawson TM,Dawson VL.Mediation of cell death by poly(ADP-ribose) polymerase-1[J]. Pharmacol Res,2005,52(l):5-14
[16]Pacher P,Szabo C.Role of poly(ADP-ribose)polymerase-1(PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors[J]. Cardiovasc Drug Rev,2007,25(3):235-260
[17]Yu SW,Wang H,Poitras MF,et al.Mediation of poly(ADP-ribose)polymerase-1 dependent cell death by apoptosis inducing factor[J].Science,2002,297(5579):259-261
[18]Dieckmann A, Kriebel M, Andriambeloson E, Ziegler D and Elmlinger M. Treatment with ActoveginR improves sensory nerve function and pathology in streptozotocin-diabetic rats via mechanisms involving inhibition of PARP activation[J].Exp Clin Endocrinol Diabetes,2012,120:132-138
[19]NiWa T.Dialysisrelated amyloidosis:pathogenesis focusing on AGE modif-ication[J].Semin Dial,2001,14(2):123-126
[20]King RHM.The role of glycation in the pathogenesis of diabetic polyneuropathy[J].J Clin pathol Mol Pathol,2001,54(6):400-408
[21]陆帮超,王坚.晚期糖基化终产物及其受体在糖尿病周围神经病变中的作用[J].中国神经免疫学和神经病学杂志,2007,14(6)：367-369
[22]Vincent AM,Perrone L, Sullivan KA,et al.Receptor for advanced glycation end productor activation injures primary sensory neurons via oxidative stress[J].Endocrinology,2007,148(2):548-558
[23]Ann Ms,Shi DYJean Lue,et al.Activation of receptor for advances Glycation End products[J].Circulation Research,1999,84:489-497
[24]Schmidt AM, et al.RAGE:a noval cellular receptor for advanced glycation end products[J].Diabetes,1996,45(suppl3):77
[25]Cellek S,Qu W,Schmidt AM,et al.Synergistic action of advanced glycation end products and endogenous nitric oxide leads to neuronal apoptosis in vitro:a new insight into selective neurergic neuropathy in diabetes[J].Diabetologia 2004,47(2):331-339
[26]Sina AA,Suginoto K.Experinental diabetic neuropathy: an up date[J].Diabetologia,1999,42(7):773
[27]Kubo E,Urakami T,Fatma N,et al. Polyri pathway-dependent osmotic and oxidative stresses in aldose reductase mediated apoptosis in human lens epithelial cells:role of A0P2[J].Biochem Biophys Res Commun,2004,314(4):1050-1056
[28]Michael B.Biochemistry and Molecular cell biology of diabetic complications[J].Nature,2001,414(6865):813-820
[29]Vinik AI.Diabetic neuropathy:pathogenesis and therapy[J].Am JM ed,1999,30: 107(2B):175
[30]Cosetino F,Eto M,De paolis p,et al.High glucose causes upregulation of cyclooxygenase-2 and alters prostanoid profile in human endothelial cells:role of protein kinase C and reactive oxygen species[J].Circulation 2003,107(7):1017-1023
[31]A Nitta,R Murai,N Suzuki,et al.Diabetic neuropathies in brain are induced by deficiency of BDNF[J].Neurotoxicology and Teratology,2002,24:695-701
[32]Quattrini C, Jeziorska M, Boulton AJ, et al. Reduced vascular endothelial growth factor expression and intra-epidermal nerve fiber loss in human diabetic neuropathy[J].Diabetes Care.2008,31 (1):140-145
[33]刘京生,孙正义,王宏沛.白介素-1和神经生长因子对周围神经再生的影响[J].中国临床康复,2002,6(18)：69-61
[34]苏会璇.糖尿病周围神经病变的发病机制[J]Clin Neurol.Oclober,2003,16(5)：314
[35]高志峰,冯艺,鞠辉,杨拨弦.神经生长因子在糖尿病神经病理性疼痛大鼠脊髓和背根神经节中的表达[J].临床麻醉学杂志,2009,25(2)：147-150
[36]Dyck PJ,Peroulka S,Rusk C,et al.Intradermal recombinant human nerve growth factor induces pressure allodynia and lowered heat-pain threshold in human[J].Neurology,1997,48:501
[37]Sullivan KA, Kim B, Feldman EL. Insulin-like growth factors in the peripheral nervous system[J].Endocrinology,2008,149(12):5963
[38]徐静,张春虹,王俊宏,王学良,袁晓红,张喜民.胰岛素样生长因子-Ⅰ与糖尿病下肢血管病变的关系[J].西安交通大学学报：医学版,2007,28(4)：434-450
[39]Delva P,Pastori C,Montesi G.Intralymphocyte free magnesium and insulin tolerance test in a group of essential hypertensive patients [J]. Life Science,1998,63:14-15
[40]Sayers NM,Besw ick LJ,Middlem as A,et al.Neurotrophin-3prevents the proximal accumulation of neurofilament proteins in sensory neurons of streptozocin-induced diabetic rats[J].Diabetes,2003,52(9):23-32
[41]熊丽丽,陈泽奇,黄娟,傅擎宇.加味补肝汤对糖尿病大鼠坐骨神经脑源性神经生长因子表达的影响[J].中国中医药信息杂志,2008,15(12)：42-44
[1]秦玖刚.补肾活血汤治疗糖尿病周围神经病变68例临床观察[J].四川中医,2007,25(6)：48-49
[2]赵丹.当归四逆汤治疗糖尿病周围神经病变30例[J].吉林中医药,2006,26(4)：28
[3]李谷松.糖尿病并发症证治[J].新中医,1990,22(9)：13
[4]张兰,陈盛业.DPN"洛损”中医辩证属性的研究[J].中国中医药现代远程教育,2008,6(8)：886-888
[5]全小林,倪青,宋军.糖尿病中医防治指南解读[M].北京：中国中医药出版社,2009,110-129
[6]陈谦.吕仁和治疗治疗糖尿病周围神经病变经验[J].中国医药学报,2002,17(1)：35
[7]赵秉祥.从气血论治糖尿病周围神经病变[J].辽宁中医杂志,2004,31(12)：995-996
[8]胡晓玲,张卫华.从脾胃本虚、痰瘀毒标论述糖尿病周围神经病变[J].新疆中医药,2006,24(1)：1-2
[9]詹继红.糖尿病周围神经病变从肝论治[J].贵阳中医学院学报,1999,21(4)：34-35
[10]吴兆利.糖尿病周围神经病变从血瘀论治[J].中国中西医基础医学杂志,2002,8(3)：23
[11]张兰,于世家.糖尿病周围神经病变瘀血洛损病机探微[J].新中医,2002,34(10)：6
[12]孙振武.糖尿病周围神经病变辩治例析[J].实用中医内科杂志,2009,23(6)：71-72
[13]于秀振.吕仁和教授辩治糖尿病周围神经病变经验[J].中级医刊,1997,32(12)：42-43
[14]李国建.辨证论治治疗糖尿病周围神经病变42例分析[J].中国实用神经疾病杂志,2008,11(12)：88-89
[15]刘春红,范冠杰,唐咸玉.补阳还五汤治疗糖尿病周围神经病变42例临床疗效观察[J].四川中医,2003,21(10)：31-32
[16]苏根.补阳还五汤治疗糖尿病周围神经病变临床观察[J].河南中医,2004,24(4)：66-67
[17]周晖,补阳还五汤合六味地黄汤治疗糖尿病周围神经病变[J].河南中医,2003,23(1)：29
[18]杨丽莉.黄芪桂枝五物汤加减治疗糖尿病周围神经病变40例[J].河南中医中医,2013,33(6)：853-854
[19]张烨雄,王珺洁.黄芪桂枝五物汤配合西药治疗糖尿病周围神经病变疗效观察[J].陕西中医,2013,34(4)：414-415
[20]王祥.黄茂桂枝五物汤联合甲钻胺治疗糖尿病周围神经病变随机平行对照研究[J].实用中医内科杂志,2013,27(7)：123-125
[21]盛庆祥.加味黄芪桂枝五物汤治疗糖尿病周围神经病变38例[J].湖南中医杂志, 2008,24(6)：451
[22]雷国大.血塞通胶囊治疗糖尿病周围神经病变的临床观察[J].中西医结合心脑血管病杂志,2006,4(6)：537-538
[23]蔡瑞玉.血塞通联合维生素B12治疗糖尿病周围神经病变临床疗效观察[J].实用糖尿病杂志,2013,9(6)：22-23
[24]吕贵德.益肾通络胶囊治疗糖尿病周围神经病变66例[J].湖北中医杂志,2004,24(6)：33
[25]吴兆利.糖未宁煎剂对DPN血瘀证患者血液流变学的影响[J].辽宁中医杂志,2002,29(4)：207
[26]王丽伟,李俊成.川芎注射液和氟桂利嗪治疗糖尿病周围神经病变[J].医药论坛杂志,2009,(02)：88-89
[27]樊永方,翁孝刚,窦敬芳.川芎嗪治疗糖尿病周围神经病变的临床观察[J].中国中西医结合杂志,1999,19(9)：550-551
[28]于斌,姜喆.盐酸川芎嗪治疗糖尿病周围神经病变疗效观察[J].长春中医药大学学报,2007,23(1)：39
[29]赵彩霞.足浴疗法治疗糖尿病周围神经病变74例临床观察[J].河北中医药学报,2001,16(1)：25
[30]王晓娜,董永利.熏洗方辅助治疗糖尿病周围神经病变的观察与护理[J].实用中医内科杂志,2007,21(5)：80
[31]赵迪.中药足浴治疗糖尿病周围神经病变疗效观察[J].辽宁中医杂志,2007,34(4)：452-453
[32]玉红,陈泽奇,叶仁群,贺钰磊.加味补肝汤对糖尿病周围神经病变大鼠背根节P38丝裂素活化蛋白激酶表达的干预作用[J].中国临床康复,2006,10(7)：67
[33]叶仁群,陈泽奇,李玉红,贺钰磊,林国彬,谢嘉嘉.加味补肝汤对实验性糖尿病大鼠坐骨神经NGF表达的影响[J].北京中医药大学学报,2007,30(2)：90-93
[34]叶仁群,陈泽奇,熊丽丽,李玉红,贺钰磊,林国彬,凌江红,申定珠.加味补肝汤对糖尿病大鼠背根节细胞凋亡的影响[J].湖南中医药大学学报,2008,28(5)：44-47
[35]熊丽丽,陈泽奇,黄娟,傅擎宇.加味补肝汤对实验性糖尿病大鼠坐骨神经BDNF表达的干预作用[J].实用预防医学,2008,15(6)：1683-1686
[36]傅擎宇,熊丽丽,陈泽奇,黄娟,戴幸平.加味补肝汤对糖尿病周围神经病变大鼠坐骨神经VEGF表达的干预作用[J].中国中医药科技,2008,15(6)：413-415
[37]傅擎宇,熊丽丽,陈泽奇,黄娟.加味补肝汤对实验性糖尿病大鼠坐骨神经PKC-βⅡ表达的影响[J].湖南中医药大学学报,2009,29(1)：29-32
[38]黄文智,梁晓春,王普艳,赵丽,李伯武,张彦东.筋脉通对实验性糖尿病坐骨神经AGEs及其受体表达的影响[J].中华中医药杂志,2011,26(4)：806-809
[39]屈岭,梁晓春,吴群励,孙连庆,赵丽,陈锡萍,钟定荣.筋脉通对糖尿病大鼠周围神经组织神经生长因子表达的影响[J].中国中药杂志,2008,33(21)：2539
[40]孙连庆,梁晓春,张宏,吴群励,屈岭,赵丽,顾蓓.中药筋脉通对高糖培养雪旺细胞增殖及NGF表达的影响[J].中华中医药杂志,2009,24(8)：1019-1022
[41]吴群励,梁晓春,孙连庆,屈岭,赵丽,王普艳.筋脉通对糖尿病大鼠周围神经组织睫状神经营养因子表达的影响[J].全国中医药中青年科技创新与成果展示论坛论文集,2011,中医药基础研究：319-324
[42]吴群励,张宏,朴元林,屈岭,孙连庆,王普艳,石玥,高云周,梁晓春.筋脉通胶囊通过增强背根神经节Nrf2和HO-1的表达改善糖尿病大鼠的周围神经痛[J].基础医学与临床,2014,34(2)：179-184
[43]吴群励,梁晓春,高云周,屈岭,孙连庆,赵丽,石玥.筋脉通胶囊对糖尿病大鼠坐骨神经神经生长因子受体p75NTR及TrkA表达的影响[J].北京中医,2013,32(7)：548-552
[44]吴群励,梁晓春,张宏,屈岭,孙连庆,赵丽,顾蓓.中药筋脉通含药血清对高糖培养雪旺细胞NF-KB表达的影响[J].世界中西医结合杂志,2011,6(6)：478-481
[45]李柏武,梁晓春,王普艳,赵丽,黄文智.筋脉通对糖尿病大鼠坐骨神经NADPH氧化酶P22-Phox亚基表达的影响[J].医学研究杂志,2011,40(5)：43-46
[46]张效科,段玉红,孟凡冰.复方中药干预糖尿病周围神经病早期病变的机理研究[J].陕西中医,2008,29(6)：755-756
[47]张效科,孟凡冰,段玉红.消渴通痹颗粒防治糖尿病周围神经病病变大鼠IL-1β、TNF-a及CD54的影响[J].陕西医学杂志中医,2008,37(6)：1136-1137
[48]王嘉新,何国芬,贡克明,张辉.槲皮素对糖尿病大鼠周围神经病变的保护作用[J].中国药理与毒理学杂志,1997,11(3)：233
[49]王启慧.糖尿病单味中药作用机理研究概述[J].安徽中医学院学报,1999,(4)：58
[50]马松涛,王秋林,张效科.桑白皮提取物对实验性糖尿病神经病变的保护作用[J].中华中医药杂志,2006,21(12)：776-777
[51]马松涛,张效科.桑白皮提取物对糖尿病大鼠神经生长因子、碱性髓鞘蛋白表达的影响[J].中国中医基础医学杂志,2007,13(10)：760-761
[52]马松涛.桑白皮提取物对防治糖尿病大鼠神经病变实验研究[J].中药药理与临床,2006,22(34)：117-118
[53]马松涛,王秋林,张效科.桑白皮提取物对糖尿病大鼠坐骨神经传导速度及生化功能的影响[J].中国药房,2007,18(3)：174-176
[54]游龙,王耕.影响血糖升降的65种中药[J].中国中医药信息杂志,2007,7(5)：32-33
[55]华文进,卜平.糖尿病周围神经病变的中西医结合治疗进展[J].医学研究生学报,2008,21(11)：1219-1221
[56]逢紫千,王朝辉,朱丹,叶玉琴.早期针刺干预补对糖尿病周围神经病变大鼠坐骨神经电生理的影响[J].吉林中医药,2010,30(9)：808-810
[57]董彦敏,李慧林,倪青,马慧芳,睢明河.针刺对糖尿病周围神经病变治疗作用的实验研究[J].北京中医药大学学报,2006,13(2)：7-10
[58]郑敏,张秋娟,东红升,施茵,杨强.针刺结合治疗糖尿病周围神经病变大鼠的实验研究[J].时珍国医国药,2009,20(8)：2006-2008
[59]向婷,王华.“双固一通”灸法对DPN大鼠坐骨神经传导速度和超微结构影响的研究[J].辽宁中医药大学学报,2010,12(5)：242-244
[60]孙远征,王伟华,毛翔.温针对大鼠糖尿病周围神经病变坐骨神经传导速度及MDA、SOD、TAOC的作用[J].上海针灸杂志,2011,30(2)：134-136
[61]苏纪武,毛翔,孙远征,王伟华.温针灸对糖尿病大鼠坐骨神经AGEsmRNA、 RAGEmRNA表达的影响[J].针灸临床杂志,2010,26(2)：51-54
[1]Ziegler, D.& A. Bierhaus.2007. Therapie der diabetischen Neuropathie[J]. Dtsch. Med.Wochenschr.132:11-16
[2]Agroff, C.E, B.E. Cole, D.A. Fishbain, et al.2006. Diabetic peripheral neuropathic pain: clinical and quality-oflife issues[J]. Mayo Clin. Proc.81(4 Suppl):S3-S11
[3]许曼音,陆广华,陈名道.糖尿病学[M].上海：上海科学技术出版社,2003：423-434
[4]朱禧星.现代糖尿病学[M].上海科学技术出版社,2000,11：333-340
[5]吕仁和,张法荣,高彦彬.消渴病(糖尿病)的分期辨证与疗效评价标准[J].中国医药报,1993,8(3)：50-56
[6]Kawai T, Takei I, Tokui M, Funae O, Miyamoto K, Tabata M, Hirata T, Saruta T,Shimada A, Itoh H. Effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy in patients with type 2 diabetes, in relation to suppression of N(ε)-carboxymethyl lysine[J]. J Diabetes Complications.2010,24(6):424-432
[7]Andrew J, M Boulton, FRCP, Arthur I, Vinik, et al. Diabetic Neuropathies:A statement by the American Diabetes Association[J].Diabetes Care,2005,28:956-962
[8]Argoff CE, Cole BE, Fishbain DA, Irving GA. Diabetic peripheral neuropathic pain: clinical and quality-of-life issues[J].Mayo Clin Proc,2006,81:S3-11
[9]Leinninger GM, Vincent AM, Feldman EL. The role of growth factors in diabetic peripheral neuropathy [J]. J Periph Nerv Syst,2004,9:26-53
[10]Brownlee M. The pathobiology of diabetic complications:a unifying mechanism[J]. Diabetes,2005,54 (6):1615-1625
[11]Schmeichel AM, Schmelzer JD, Low PA. Oxidative injury and apoptosis of dorsal root ganglion neurons in chronic experimental diabetic neuropathy [J].Diabetes,2003,52 (1):165-171
[12]Feldman EL. Oxidative stress and diabetic neuropathy:a new understanding of an old problem[J].J Clin Invest,2003,111(4):431-433
[13]陈谦.吕仁和治疗治疗糖尿病周围神经病变经验[J].中国医药学报,2002,17(1)：35
[14]赵秉祥.从气血论治糖尿病周围神经病变[J].辽宁中医杂志,2004,31(12)：995-996
[15]胡晓玲,张卫华.从脾胃本虚、痰瘀毒标论述糖尿病周围神经病变[J].新疆中医药,2006,24(1)：1-2
[16]张兰,于世家.糖尿病周围神经病变瘀血洛损病机探微[J].新中医,2002,34(10)：6
[17]游龙,王耕.影响血糖升降的65种中药[J].中国中医药信息杂志,2000,7(5)；32-33
[18]范征吟,叶信莉.自拟“糖宁Ⅲ号合剂”治疗Ⅱ型糖尿病的研究[J].上海中医药杂志,2000,34(5)：14-16
[19]韩喻美.Fura-2荧光测定中药有效成分对神经细胞内Ca2+浓度的变化[J].江西医学院学报,1996,36(4)：11
[20]周中和,曲方,何祥.局部应用重组水蛭素对大鼠脑出血神经细胞凋亡的干预作用阴.临床神经病学杂志,2006,19(4)：304-306
[1]Wild S, Roglic G, Green A, Sicree R, King H: Global prevalence of diabetes:estimates for the year 2000 and projections for 2030[J]. Diabetes Care,2004,27:1047-1053
[2]王佳,刘铜华.糖痹康对糖尿病大鼠血清神经性因子及坐骨神经神经性因子基因表达的影响[J].中国实验方剂学杂志,2010,16(6)：160-163
[3]王佳,刘铜华.糖痹康对糖尿病周围神经病变大鼠坐骨神经传导速度的影响[J].中国中医基础医学杂志,2010,16(3)：209-211
[4]王佳,刘铜华.糖痹康对大鼠糖尿病周围神经病变氧化应激影响的实验研究[J].国际中医中药杂志,2010,10(4)：211-238
[5]穆晓红,刘铜华,秦灵灵,王磊,吴丽丽,李娟娥,孙文,张宏.从血液流变学和坐骨神经传导速度评价中药糖痹康对大鼠糖尿病周围神经病变的影响[J].中华中医药杂志,2012,27(2)：378-381
[6]吴晏,韩静,黄黎明,郭淑贞,王伟.高脂喂养合并小剂量链脲佐菌素建立2型糖尿病大鼠模型[J].中国实验动物学报,2012,20(2)：11-15
[1]Argoff C E,Cole B E,Fishbain D A,et al.Diabetic peripheral neuropathic pain:clinical and quality-of-life issues[J].Mayo Clin Proc,2006,81:3-11
[2]姚鸿萍,封卫毅,魏友霞,董海燕.大鼠坐骨神经传导速度测定的方法学考察[J].中国药房,2011,1(22)：18-20
[3]吴丙云,鲁珊珊,刘莹.糖尿病周围神经病分型及神经电生理检查研究进展[J].山东医药,2007,(17)：96-97
[4]杨廷强,朱瑾,李秀钧.大剂量甲钴胺治疗糖尿病周围神经病变疗效观察[J].华西医学,2007,22(1)：131
[5]魏立新,顾德新.甲钴胺联合血塞通治疗糖尿病周围神经病变的临床观察[J].中国医学创新,2011,8(7)：162-163
[6]Li ZG, Zhang W, Sima AAF. C2peptide prevents hippocampal apoptosis in type 1 diabetes[J]. Int Exp Diabetes Res,2002,3 (4):241-246
[7]Ji Woong Han, Min Young Sin, Young-sup Yoon. Cell Therapy for Diabetic Neuropathy Using Adult Stem or Progenitor Cells[J]. Diabetes Metab J,2013,7:91-105
[8]刘彩艳,魏健,徐栋.鲑鱼降钙片治疗糖尿病周围神经病变疼痛及p-内啡肽变化[J].实用医药杂志,2004,21(3)：201-204
[9]沈祥峰,柴可夫,杨明华.运脾和络颗粒对糖尿病周围神经病变大鼠血浆p-内啡肽的影响[J].中华中医药学刊,2011,29(1)：125-127
[10]曲秋菊,冯立群.血管活性因子改变糖尿病周围神经病微血管内皮损伤机制[J].国际神经病学神经外科学杂志,2010,37(1)：53-54
[11]郭蔚莹,刘艳,朱丹.二型糖尿病合并周围神经病变内皮素及一氧化氮水平监测[J].中国实验诊断学,2005,9(3)：413-414
[1]吴晏,韩静,黄黎明,郭淑贞,王伟.高脂喂养合并小剂量链脲佐菌素建立2型糖尿病大鼠模型[J].中国实验动物学报,2012,20(2)：11-15
[2]Mithieux G, Guignot L, Bordet JC, et al. Intrahepatic mecha-nisms underlying the effect of metformin in decreasing basal glu-cose production in rats fed a high-fat diet[J]. Diabetes,2002,51; 139-143
[3]Chan CB, De Leo D, Joseph JW, et al. Increased uncoupling protein-2 levels in P-cells are associated with impaired glucose-stimulated insulin secretion:mechanism of action[J]. Diabetes,2001,50; 1302-1310
[4]Reimer MK, Aher NB. Altered β-cell distribution of pdx-1 andGLUT-2 after a short-term challenge with a high-fat diet in C57BL/6J mice[J]. Diabetes,2002,51:S138-S143
[5]卜石,杨文英,王昕,刘雪莉,陈仕明,湛玉良.长期高脂饲养对大鼠葡萄糖刺激的胰岛素分泌的影响[J].中华内分泌代谢杂志,2003,19：25-28
[6]周中和,曲方,何祥.局部应用重组水蛭素对大鼠脑出血神经细胞凋亡的干预作用[J].临床神经病学杂志,2006,19(4)：304-306
[7]MC Garry D. Banting lecyure 2001:Dysregulation of fatty acid metabolism in the etiology of type2 diabete[J]. Diabetes,2002,51(1):7-18
[8]Costa J,Borges M,David C,et al.Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patient:meta-analysis of randomised controlled trials[J].2006,332:1115-24
[9]Yamakawa I, Kojima H, Terashima T, Katagi M, Oi J, Urabe H, Sanada M, Kawai H, Chan L, Yasuda H, et al. Inactivation of TNF-aameliorates diabetic neuropathy in mice[J]. Am J Physiol Endocrinol Metab,2011,301:E844-852
[10]Cameron VF, Gibson TM, Vangle MR, et al. Inhibitors of advanced glvcati on end products formation and neurovascular dysfunction in experimental diabetes[J]. Ann N Y Acad Sci,2005,1043:784-792
[11]Tesfaye S, Chaturvedi N, Eaton S E, et al. Vascular risk factors and diabetic neuropathy [J]. N Engl J Med,2005,352:341-350
[1]Vinik AI.Diabetic neuropathy:pathogenesis and therapy[J].Am JM ed,1999,30:107(2B):175
[2]Quattrini C, Jeziorska M, Boulton AJ, et al. Reduced vascular endothelial growth factor expression and intra-epidermal nerve fiber loss in human diabetic neuropathy [J]. Diabetes Care,2008,31(1):140-145
[3]苏会璇.糖尿病周围神经病变的发病机制[J].Clin Neurol.Oclober,2003,16(5):314
[4]Aauda H,Terada M,Maeda K,et al. Diabetic neuropathy and nerve regeneration[J]. Prog Neurobiol,2003,69(4):229
[5]刘京生,孙正义,王宏沛.白介素-1和神经生长因子对周围神经再生的影响[J].中国临床康复,2002,6(18)：26961
[6]高志峰,冯艺,鞠辉,杨拨贤.神经生长因子在糖尿病神经病理性疼痛大鼠脊髓和背根神经节中的表达[J].临床麻醉学杂志,2009,25(2)：147-150
[7]Dyck PJ,Peroulka S,Rusk C,et al.Intradermal recombinant human nerve growth factor induces pressure allodynia and lowered heat-pain threshold in human [J]. Neurology,1997,48:501
[1]Vinik AI.Diabetic neuropathy:pathogenesis and therapy[J].Am JM ed,1999,30:107(2B):175
[2]Qi S, Zhan RZ,Wu C, et al. The effects of thiopen tal and propofol on cell swelling induced by oxygen/glucose cell layer of rat hippocampal slicers[J].Anesth Analg,2002,94(3):655-660
[3]A Nitta, R Murai, N Suzuki, et al. Diabetic neuropathies in brain are induced by deficiency of BDNF[J].Neurotoxicology and Teratology,2002,24:695-701
[4]叶仁群,陈泽奇,李玉红,贺钰磊,林国彬,谢嘉嘉.加味补肝汤对糖尿病大鼠坐骨神经NGF表达的影响[J].北京中医药大学学报,2007,30(2)：90-94
[5]A Tsuchida,T Nonomura, M Ono-Kishino. Acute effects of brain-derived neurotrophic factor on energy expenditure in obese diabetic mice[J].Obesity,2001,25(9):1286-1293
[6]Tolwani RJ, Cosgaya JM, Varma S, Jacob R, Kuo LE, Shooter EM. BDNF overexpression produces a long-term increase in myelin formation in the peripheral nervous system[J]. Neurosci Res.2004,77:662-669
[7]熊丽丽,陈泽奇,黄娟,傅擎宇.加味补肝汤对糖尿病大鼠坐骨神经脑源性神经生长因子表达的影响[J].中国中医药信息杂志,2008,15(12)：42-44
[1]Vinik AI.Diabetic neuropathy: pathogenesis and therapy[J]. Am JM ed,1999,30: 107(2B):175
[2]Lim PA,Tow AM.Recovery and regeneration after spinal cord injury: a review and summary of recent literature[J]. Ann Acad Med Singapore,2007,36(1):49-57
[3]Dumont RJ,Verma S,Okonkwo DO, et al.Acute spinal cord injury,part Ⅱ:contemporary pharmacotherapy[J]. Clin Neuropharmacol,2001,24(5):265-79
[4]Reyes O,Soas I,Kuffler DP,Neuroprotection of spinal neuropns against blunt trauma and ischemia[J]. PR Healht Sci J,2003,22(3):277-86
[5]Kirshbium SC,Groah SL,McKinley WO,et al. Spinal cord injury medicine 1. Etiology classification and acute medical managemen[J].Areh Phys Med Rehabil,2002,83(3 Suppl):S50-57-S90-98
[6]Sekhon LS,Fehlings MG.Epidemiology,demographic,and pathophysiology of acute spinal cord injury[J].Spine,2001,26(24S):S2-12
[7]Buxton N.The military medicine management of missile injury to the spine:a review of the literature and proposal of guidelines[J]. RArmyMed Corps,2001,147(2):168-172
[8]Jacobs WB,Fehlings MG.The molecular basis of neural regenration neurosurgery[J]. Am JM ed,2003,53(4):943-948
[9]Qin Dx, Zou xl, Luow, et aL.Expression of some neurotrophins in the spinal motoneurons after cord hemisection in adult rats[J].Neurosci Lett,2006,410(3):222-227
[10]Li x-L,Zhang W,Zhou X, et al.Tempral changes in the expression of some neurotrophins in spinal cord transected adult rats[J].Neuropeptides,2007, April 23, Epub ahesd of print
[11]Sayers NM,Besw ick LJ,Middlem as A, et al. Neurotrophin-3prevents the proximal accumulation of neurofilament proteins in sensory neurons of streptozocin-induced diabetic rats[J]. Diabetes,2003,52(9):2372
[12]Bae Jin Kim, Hee Kyung Jin, Jae-Sung Bae. Bone Marrow-Derived Mesenchymal Stem Cells Improve the Functioning of Neurotrophic Factors in a Mouse Model of Diabetic Neuropathy[J]. Lab Anim Res,2011,27(2):171-176
[1]Vinik AI.Diabetic neuropathy:pathogenesis and therapy[J]. Am JM ed,1999,30: 107(2B):175
[2]Verheul HM, Pinedo HM. Vascular endothelial growth factor and its inhibitors[J]. Drugs Today,2003,39 Suppl C:81-93
[3]Sung JK, Koh JH, Lee MY, et al. Aldose reductase inhibitor ameliorates renal vascular endothelial growth factor expression in streptozotocin-induced diabetic rats[J]. Yonsei Med J,2010,51:385-391
[4]Quattrini C,Jeziorska M,Boulton AJ, et al. Reduced vascular endothelial growth factor expression and intra-epidermal nerve fiber loss in human diabetic neuropathy[J].Diabetes Care,2008,31:140-145
[5]Sondell M, Sundler F, Kanje M. Vascular endothelial growth factor is a neurotrophic factor which stimulates axonal outgroth through the flk-1 receptor[J]. Eur J Neurosci, 2000,12:4243-4254
[6]Hobson MI, Green CJ, Terenghi G. VEGF enhances intraneural angiogenesis and improves nerve regeneration after axotomy[J]. J Anat,2000,197:591-605
[7]Samii A, Unger W, Lange W. Vascular endo thelial grow th facto r in peripheral nerve and do rsal root ganglia in diabeticneuropathy in rats.[J]. Neuro sciL ett,1999,262:159-162
[8]王巍,于世家,谢映红.糖末宁颗粒对糖尿病周围神经病变大鼠坐骨神经血管内皮生长因子表达的影响[J].中华保健医学杂志,2012,14(2)：19-21
[1]Magnani P, Thomas TP, Tennekoon G, et al. Regulation of glucose transport in cultured Schwann cells[J]. J Peripher Nerv Syst,1998,3:28-36
[2]Scarpini E, Doronzo R, Baron P, et al. Phenotypic and proliferative properties of Schwann cells from nerves of diabetic patients[J]. Int J Clin Pharmacol Res,1992,12(5-6):211-215
[3]Ide C. Peripheral nerve rege neration[J]. Neurosci Res,1996,25:101-121
[4]Dubovy R Schwann cells and endoneurial extracellular matrix molecules as potential cues for sorting of regenerated axons:a review[J]. Anat Sci Int,2004,79:198-208
[5]Chen Zl,Yu Wm, Strickland S. Peripheral regeneration[J]. Amu Rev Neurosci,2007,30: 209-233
[6]王筠,张军平.中药血清药理学实验方法概述[J].天津中医药,2005,22(1)：86-88
[7]张宏,刘铜华.糖痹康对高糖损伤人脐静脉内皮细胞的保护作用[J].中华中医药期刊,2012,30(6)：1248-1251
[8]穆晓红.糖痹康干预糖尿病周围神经病变神经保护作用及机制研究,2011年博士后出站报告
[1]潘长玉译Joslin糖尿病学(14版)[M].北京：人民卫生出版社,2007： 988
[2]CobbMH.MAPkinasePathways [J]. ProgBioPhysMolBiol.1999,71(3-4):479-500
[3]JinSX,ZhuangZY,woolfCJ,etal.P38Mitogen-activated Protein kinase is activated After as Pinal nerve ligation in spinal cord microglia and dorsal root ganglion neurons and contributes to the generation of neuropathic pain[J]. Neurosci,2003,23(10):4017-4022
[4]Piao AG,Cho IH,Park CK.Activation of glia and microglial P38MAPK in medullary Dorsal horn contributes to tactile hyPersensitivity following trigeminal sensory nerve injury[J].Pain,2006,121(3):219-31
[5]Deleroix JD,Vallellu JS,Wu C,et al.NGF signaling in sensory neurons:evidence that early endosomes carry NGF retrograde signals [J]. Neuron,2003,39(1):69-84
[6]Schafers M,Svensson Cl,Sommer C,et al.Tumor necrosis factor-alPha induces mechanical Allodynia after sPinal nervel igation by activation of P38MAPK in Primary sensory neurons[J].Neurosei,2003,23(7):2517-2521
[7]Hall GC,Carroll D,parry D, McQuay HJ. Epidemiology and treatment of neuro-pathic Pain:the UK Primary care PersPeetive[J].Pain,2006,122:156-162
[8]Moalem G, Tracey DJ. Immune and inflammatory mechanisms in neuroPathic Pain[J]. Brain Res Rev,2006,51:240-264
[9]Bolin LM,Verity AN,silver JE,shooter EM, Abrams Js. Interleukin-6 produetion By Schwann cells and induction insciatic nerve injury[J]. Neuroehem,1995,64:850-858
[10]Shamash S,Reiehert F, Rotshenker S. The cytokine network of Wallerian degeneration:tumor necrosis factor-alPha,interleukin-lalPha,and inter-leukin-1 beta[J]. Neurosci,2002,22:3052-3060
[11]EmPI M,Renaud S,Erne B,Fuhr P,Straube A,Schaeren-Wiemers N,Steck AJ:TNF-alpha eXPression in Painful and nonPainful neuroPathies[J].Neurology,2001,56:1371-1377
[12]Schafers M,Svensson C1,Sommer C, Sorkin LS. Tumor necrosis factor alPha Induces mechanical allodynia after sPinal nerve ligation by activation of P38MAPK in Primary sensory neurons[J].Neurosci,2003,23:2517-2521
[13]Matsumoto K, Sera Y, Ueki Y, et al. Comparison of serum concentrations of soluble adhesion molecules in diabet ic microangiopathy and macroangiopathy[J]. Diabet Med, 2002,19:822-828
[14]王加林,赵亚平,周玮等.Ⅱ型糖尿病患者血清sICAM-1和sVCAM-1检测及其临床意义[J].免疫学杂志,1999,15：120-121
[15]杨虹,卢学勉,叶成夫,陈良苗.血清sVCAM-1和sICAM-1的变化与DPN的关系 [J].辽宁实用糖尿病杂志,2004,12(2)：19-20
[16]Yagihashi S,Pathology of diabetic neuropathy,a review from the up dated literature of the last 10 years[J]. Nippon Rinsho,2002,60suppl 12:200-204